BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bang Y, Kim Y, Yang H, Chung HC, Park Y, Lee KH, Lee K, Kim YH, Noh S, Cho JY, Mok YJ, Kim YH, Ji J, Yeh T, Button P, Sirzén F, Noh SH. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. The Lancet 2012;379:315-21. [DOI: 10.1016/s0140-6736(11)61873-4] [Cited by in Crossref: 866] [Cited by in F6Publishing: 528] [Article Influence: 96.2] [Reference Citation Analysis]
Number Citing Articles
1 Qiu MZ, He CY, Yang DJ, Zhou DL, Zhao BW, Wang XJ, Yang LQ, Lu SX, Wang FH, Xu RH. Observational cohort study of clinical outcome in Epstein-Barr virus associated gastric cancer patients. Ther Adv Med Oncol 2020;12:1758835920937434. [PMID: 32670421 DOI: 10.1177/1758835920937434] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Tang C, Feng W, Bao Y, Chen C. Maintenance Chemotherapy with S-1 Following SOX Regimen Chemotherapy Improves Prognosis of Stage 3 Gastric Cancer After D2 Gastrectomy: A 5-Year Analysis. Onco Targets Ther 2020;13:12661-6. [PMID: 33324076 DOI: 10.2147/OTT.S271884] [Reference Citation Analysis]
3 Takahashi R, Nunobe S, Makuuchi R, Ida S, Kumagai K, Ohashi M, Sano T. Survival outcomes of elderly patients with pathological stages II and III gastric cancer following curative gastrectomy. Ann Gastroenterol Surg 2020;4:433-40. [PMID: 32724887 DOI: 10.1002/ags3.12339] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Kim DW, Kwon OK, Yoo MW, Ryu SW, Oh SJ, Hur H, Hwang SH, Lee J, Jin SH, Lee SE, Kim JH, Kim JJ, Jeong IH, Jee YS. Actual compliance to adjuvant chemotherapy in gastric cancer. Ann Surg Treat Res 2019;96:185-90. [PMID: 30941322 DOI: 10.4174/astr.2019.96.4.185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
5 Liu X, Cai H, Shi Y, Wang Y. Prognostic factors in patients with node-negative gastric cancer: a single center experience from China. J Gastrointest Surg. 2012;16:1123-1127. [PMID: 22488657 DOI: 10.1007/s11605-012-1881-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
6 Ashraf N, Hoffe S, Kim R. Locally advanced gastroesophageal junction tumor: a treatment dilemma. Oncologist 2015;20:134-42. [PMID: 25561508 DOI: 10.1634/theoncologist.2014-0377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Ahn SH, Kang SH, Lee Y, Min SH, Park YS, Park DJ, Kim HH. Long-term Survival Outcomes of Laparoscopic Gastrectomy for Advanced Gastric Cancer: Five-year Results of a Phase II Prospective Clinical Trial. J Gastric Cancer. 2019;19:102-110. [PMID: 30944763 DOI: 10.5230/jgc.2019.19.e6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
8 Stroes CI, Schokker S, Molenaar RJ, Mathôt RAA, Bijlsma MF, van der Woude SO, Belo Pereira JP, Hooijer GKJ, Verhoeven RHA, Cats A, Grootscholten C, van Sandick JW, Creemers GJ, Nieuwenhuijzen GAP, Haj Mohammad N, Ruurda JP, Meijer SL, Hulshof MCCM, van Berge Henegouwen MI, van Laarhoven HWM. A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. Cancers (Basel) 2021;13:839. [PMID: 33671266 DOI: 10.3390/cancers13040839] [Reference Citation Analysis]
9 Giuliani A, Miccini M, Basso L. Extent of lymphadenectomy and perioperative therapies: Two open issues in gastric cancer. World J Gastroenterol 2014; 20(14): 3889-3904 [PMID: 24744579 DOI: 10.3748/wjg.v20.i14.3889] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
10 Xie J, Li R. False discovery rate control for high dimensional networks of quantile associations conditioning on covariates. J R Stat Soc Series B Stat Methodol 2018;80:1015-34. [PMID: 31057329 DOI: 10.1111/rssb.12288] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Wang G, Zhao J, Song Y, Zhang W, Sun Y, Zhou A, Huang J, Du F, Yang L. Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer. BMC Cancer. 2018;18:547. [PMID: 29743043 DOI: 10.1186/s12885-018-4480-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
12 Chen L, Hao Y, Zhu L, Li S, Zuo Y, Zhang Y, Song H, Xue Y. Monocyte to lymphocyte ratio predicts survival in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy. Onco Targets Ther. 2017;10:4007-4016. [PMID: 28860808 DOI: 10.2147/ott.s140118] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
13 Araki I, Hosoda K, Yamashita K, Katada N, Sakuramoto S, Moriya H, Mieno H, Ema A, Kikuchi S, Mikami T. Prognostic impact of venous invasion in stage IB node-negative gastric cancer. Gastric Cancer. 2015;18:297-305. [PMID: 24687437 DOI: 10.1007/s10120-014-0362-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
14 Zheng Y, Li Y, Liu X, Zhang R, Wang Z, Sun H, Liu S. A phase III, multicenter randomized controlled trial of neo-adjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA-IIIB esophageal squamous cell carcinoma. J Thorac Dis 2017;9:200-4. [PMID: 28203424 DOI: 10.21037/jtd.2017.01.44] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
15 Harada S, Yanagisawa M, Kaneko S, Yorozu K, Yamamoto K, Moriya Y, Harada N. Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model. Mol Clin Oncol 2015;3:987-94. [PMID: 26623038 DOI: 10.3892/mco.2015.609] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
16 Ikoma N, Lee JH, Bhutani MS, Ross WA, Weston B, Chiang YJ, Blum MA, Sagebiel T, Devine CE, Matamoros A Jr, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography. J Gastrointest Oncol 2017;8:1009-17. [PMID: 29299361 DOI: 10.21037/jgo.2017.04.04] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
17 Wu HC, Lin WL, Lin CL, Lin CY, Chen SW, Chen YX, Chen CH, Lee SW, Chen SH, Tsao CJ, Huang WT, Guo HR. Age as a modifier of the effects of chemoradiotherapy with infusional 5-fluorouracil after D2 dissection in gastric cancer. Aging (Albany NY) 2021;13:17337-48. [PMID: 34226296 DOI: 10.18632/aging.203223] [Reference Citation Analysis]
18 Chang SC, Liu KH, Hung CY, Tsai CY, Hsu JT, Yeh TS, Chen JS, Kuo YC, Hung YS, Chou WC. Adjuvant Chemotherapy Improves Survival in Stage III Gastric Cancer after D2 Surgery. J Cancer 2018;9:81-91. [PMID: 29290772 DOI: 10.7150/jca.21989] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
19 Kim C, Mulder K, Spratlin J. How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. Oncologist. 2014;19:1046-1055. [PMID: 25142842 DOI: 10.1634/theoncologist.2014-0006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
20 Aurello P, Sagnotta A, Terrenato I, Berardi G, Nigri G, D'Angelo F, Ramacciato G. Oncologic value of laparoscopy-assisted distal gastrectomy for advanced gastric cancer: A systematic review and meta-analysis. J Minim Access Surg 2016;12:199-208. [PMID: 27279389 DOI: 10.4103/0972-9941.181283] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
21 Tian Y, Jia X, Wang S, Li Y, Zhao P, Cai D, Zhou Z, Wang J, Luo Y, Dong M. SOX2 oncogenes amplified and operate to activate AKT signaling in gastric cancer and predict immunotherapy responsiveness. J Cancer Res Clin Oncol 2014;140:1117-24. [PMID: 24752338 DOI: 10.1007/s00432-014-1660-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
22 Mihmanli M, Ilhan E, Idiz UO, Alemdar A, Demir U. Recent developments and innovations in gastric cancer. World J Gastroenterol 2016; 22(17): 4307-4320 [PMID: 27158199 DOI: 10.3748/wjg.v22.i17.4307] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
23 Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24:1-21. [PMID: 32060757 DOI: 10.1007/s10120-020-01042-y] [Cited by in Crossref: 188] [Cited by in F6Publishing: 162] [Article Influence: 188.0] [Reference Citation Analysis]
24 Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2013;2:e23510. [PMID: 23687621 DOI: 10.4161/onci.23510] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 9.9] [Reference Citation Analysis]
25 Zhao Q, Lian C, Huo Z, Li M, Liu Y, Fan L, Tan B, Zhao X, Zhang Z, Wang D, Liu Y, Guo H, Yang P, Tian Y, Li Y. The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial. Cancer Med 2020;9:5731-45. [PMID: 32583567 DOI: 10.1002/cam4.3224] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
26 Lin GS, Huang XY, Lu J, Wu D, Zheng HL, Xu BB, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Chen QY, Cao LL, Lin M, Tu RH, Lin GT, Huang ZN, Lin JL, Huang CM. A good preoperative immune prognostic index is predictive of better long-term outcomes after laparoscopic gastrectomy compared with open gastrectomy for stage II gastric cancer in elderly patients. Surg Endosc 2021. [PMID: 34076769 DOI: 10.1007/s00464-021-08461-7] [Reference Citation Analysis]
27 Chan DY, Syn NL, Yap R, Phua JN, Soh TI, Chee CE, Nga ME, Shabbir A, So JB, Yong WP. Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready? J Gastrointest Surg 2017;21:425-33. [PMID: 27981493 DOI: 10.1007/s11605-016-3336-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
28 Nakauchi M, Vos E, Janjigian YY, Ku GY, Schattner MA, Nishimura M, Gonen M, Coit DG, Strong VE. Comparison of Long- and Short-term Outcomes in 845 Open and Minimally Invasive Gastrectomies for Gastric Cancer in the United States. Ann Surg Oncol 2021;28:3532-44. [PMID: 33709174 DOI: 10.1245/s10434-021-09798-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Togano S, Yashiro M, Miki Y, Yamamoto Y, Sera T, Kushitani Y, Sugimoto A, Kushiyama S, Nishimura S, Kuroda K, Okuno T, Yoshii M, Tamura T, Toyokawa T, Tanaka H, Muguruma K, Tanaka S, Ohira M. Microscopic distance from tumor invasion front to serosa might be a useful predictive factor for peritoneal recurrence after curative resection of T3-gastric cancer. PLoS One 2020;15:e0225958. [PMID: 31940352 DOI: 10.1371/journal.pone.0225958] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
30 Lin JX, Lin JP, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu R, Zheng CH, Huang CM, Li P. Prognostic Value and Association of Sarcopenia and Systemic Inflammation for Patients with Gastric Cancer Following Radical Gastrectomy. Oncologist. 2019;24:e1091-e1101. [PMID: 30910865 DOI: 10.1634/theoncologist.2018-0651] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
31 Ma H, Tian Y, Yu X. Targeting Smoothened Sensitizes Gastric Cancer to Chemotherapy in Experimental Models. Med Sci Monit 2017;23:1493-500. [PMID: 28350784 DOI: 10.12659/msm.903012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
32 Fuse N, Bando H, Chin K, Ito S, Yoshikawa T, Tsuburaya A, Terashima M, Kawashima Y, Fukunaga T, Gotoh M, Emi Y, Yoshida K, Oki E, Takahashi S, Kuriki H, Sato K, Sasako M. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study. Gastric Cancer. 2017;20:332-340. [PMID: 26956689 DOI: 10.1007/s10120-016-0606-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
33 Ashraf N, Hoffe S, Kim R. Adjuvant treatment for gastric cancer: chemotherapy versus radiation. Oncologist 2013;18:1013-21. [PMID: 23966224 DOI: 10.1634/theoncologist.2012-0462] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
34 Meng C, Yin H, Sun Z, Zhou J, Chen S, Bai C, Zhao L. Adjuvant Chemotherapy with Docetaxel, Cisplatin, and Continuous-Infusion 5-Fluorouracil for Gastric Cancer: A Phase II Study. Transl Oncol 2014;7:277-83. [PMID: 24704535 DOI: 10.1016/j.tranon.2014.02.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
35 Raimondi A, Palermo F, Prisciandaro M, Aglietta M, Antonuzzo L, Aprile G, Berardi R, Cardellino GG, De Manzoni G, De Vita F, Di Maio M, Fornaro L, Frassineti GL, Granetto C, Iachetta F, Lonardi S, Murialdo R, Ongaro E, Pucci F, Ratti M, Silvestris N, Smiroldo V, Spallanzani A, Strippoli A, Tamberi S, Tamburini E, Zaniboni A, Di Bartolomeo M, Cremolini C, Sposito C, Mazzaferro V, Pietrantonio F. TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. Cancers (Basel) 2021;13:2839. [PMID: 34200267 DOI: 10.3390/cancers13112839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Arai H, Nakajima TE. Recent Developments of Systemic Chemotherapy for Gastric Cancer. Cancers (Basel) 2020;12:E1100. [PMID: 32354119 DOI: 10.3390/cancers12051100] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
37 Chiu CF, Yang HR, Yang MD, Jeng LB, Sargeant AM, Yeh SP, Bai LY. The role of adjuvant chemotherapy for patients with stage II and stage III gastric adenocarcinoma after surgery plus D2 lymph node dissection: a real-world observation. Springerplus 2016;5:728. [PMID: 27375997 DOI: 10.1186/s40064-016-2552-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
38 Oh SC. Update of adjuvant chemotherapy for resected gastric cancer. J Gastric Cancer. 2012;12:3-6. [PMID: 22500257 DOI: 10.5230/jgc.2012.12.1.3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
39 Lee JH, Chang KK, Yoon C, Tang LH, Strong VE, Yoon SS. Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma. Ann Surg. 2018;267:105-113. [PMID: 27759618 DOI: 10.1097/sla.0000000000002040] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 11.5] [Reference Citation Analysis]
40 Chen K, Mou YP, Xu XW, Cai JQ, Wu D, Pan Y, Zhang RC. Short-term surgical and long-term survival outcomes after laparoscopic distal gastrectomy with D2 lymphadenectomy for gastric cancer. BMC Gastroenterol. 2014;14:41. [PMID: 24568165 DOI: 10.1186/1471-230x-14-41] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
41 Ramos MFKP, de Castria TB, Pereira MA, Dias AR, Antonacio FF, Zilberstein B, Hoff PMG, Ribeiro U Jr, Cecconello I. Return to Intended Oncologic Treatment (RIOT) in Resected Gastric Cancer Patients. J Gastrointest Surg. 2020;24:19-27. [PMID: 31745892 DOI: 10.1007/s11605-019-04462-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
42 Wagner AD, Grabsch HI, Mauer M, Marreaud S, Caballero C, Thuss-Patience P, Mueller L, Elme A, Moehler MH, Martens U, Kang YK, Rha SY, Cats A, Tokunaga M, Lordick F. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone vs chemotherapy plus trastuzumab, vs chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer. 2019;19:494. [PMID: 31126258 DOI: 10.1186/s12885-019-5675-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
43 Shimizu S, Saito H, Kono Y, Murakami Y, Shishido Y, Miyatani K, Matsunaga T, Fukumoto Y, Fujiwara Y. The prognostic significance of the comprehensive complication index in patients with gastric cancer. Surg Today 2019;49:913-20. [PMID: 31147763 DOI: 10.1007/s00595-019-01828-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Lin JX, Lin JP, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu R, Zheng CH, Huang CM, Li P. Complete blood count-based inflammatory score (CBCS) is a novel prognostic marker for gastric cancer patients after curative resection. BMC Cancer 2020;20:11. [PMID: 31906893 DOI: 10.1186/s12885-019-6466-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
45 Yoshikawa T, Rino Y, Yukawa N, Oshima T, Tsuburaya A, Masuda M. Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy. Surg Today. 2014;44:11-21. [PMID: 23508452 DOI: 10.1007/s00595-013-0529-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
46 李宏伟, 杨金坤, 赵爱光. 胃癌辅助治疗的研究进展. 世界华人消化杂志 2014; 22(32): 4921-4927 [DOI: 10.11569/wcjd.v22.i32.4921] [Reference Citation Analysis]
47 Girardi DM, de Lima MA, Pereira GCB, Negrão MV, López RVM, Capareli FC, Sabbaga J, Hoff PMG. Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis. BMC Cancer 2018;18:378. [PMID: 29614980 DOI: 10.1186/s12885-018-4305-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Saragoni L. Upgrading the definition of early gastric cancer: better staging means more appropriate treatment. Cancer Biol Med 2015;12:355-61. [PMID: 26779372 DOI: 10.7497/j.issn.2095-3941.2015.0054] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
49 Hao Y, Yu P, Qian F, Zhao Y, Shi Y, Tang B, Zeng D, Zhang C. Comparison of laparoscopy-assisted and open radical gastrectomy for advanced gastric cancer: A retrospective study in a single minimally invasive surgery center. Medicine (Baltimore) 2016;95:e3936. [PMID: 27336885 DOI: 10.1097/MD.0000000000003936] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
50 Buergy D, Lohr F, Baack T, Siebenlist K, Haneder S, Michaely H, Wenz F, Boda-Heggemann J. Radiotherapy for tumors of the stomach and gastroesophageal junction--a review of its role in multimodal therapy. Radiat Oncol. 2012;7:192. [PMID: 23157945 DOI: 10.1186/1748-717x-7-192] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
51 Park DJ, Seo AN, Yoon C, Ku GY, Coit DG, Strong VE, Suh YS, Lee HS, Yang HK, Kim HH, Yoon SS. Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma. Ann Surg Oncol 2015;22 Suppl 3:S1508-15. [PMID: 26259755 DOI: 10.1245/s10434-015-4790-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
52 Aytaç E, Aslan F, Çicek B, Erdamar S, Gürses B, Güven K, Falay O, Karahasanoğlu T, Selçukbiricik F, Selek U, Atalar B, Balık E, Tözün N, Rozanes İ, Arıcan A, Hamzaoğlu İ, Baca B, Molinas Mandel N, Saruç M, Göksel S, Demir G, Ağaoğlu F, Yakıcıer C, Özbek U, Özben V, Özyar E, Güner AL, Er Ö, Kaban K, Bölükbaşı Y, Buğra D, Group Tİ. Dealing with the gray zones in the management of gastric cancer: The consensus statement of the İstanbul Group. Turk J Gastroenterol 2019;30:584-98. [PMID: 30541724 DOI: 10.5152/tjg.2018.18737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Sasako M, Terashima M, Ichikawa W, Ochiai A, Kitada K, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H. Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer. Gastric Cancer 2015;18:538-48. [PMID: 25112781 DOI: 10.1007/s10120-014-0413-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
54 Agolli L, Nicosia L. Between evidence and new perspectives on the current state of the multimodal approach to gastric cancer: Is there still a role for radiation therapy? World J Gastrointest Oncol 2018; 10(9): 271-281 [PMID: 30254722 DOI: 10.4251/wjgo.v10.i9.271] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
55 Wu Y, Wei ZW, He YL, Schwarz RE, Smith DD, Xia GK, Zhang CH. Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer. World J Gastroenterol 2013; 19(21): 3309-3315 [PMID: 23745033 DOI: 10.3748/wjg.v19.i21.3309] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
56 Park JH, Ryu MH, Kim HJ, Ryoo BY, Yoo C, Park I, Park YS, Oh ST, Yook JH, Kim BS, Kang YK. Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer. Gastric Cancer 2016;19:226-33. [PMID: 25614467 DOI: 10.1007/s10120-015-0464-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
57 Luo W, Zhang H, Zhao Y, Wang L, Qi L, Ran J, Liu L, Wu A. A retrospective study on intensity-modulated radiation therapy combined with chemotherapy after D2 radical surgery for gastric carcinoma. Mol Clin Oncol 2016;4:740-8. [PMID: 27123273 DOI: 10.3892/mco.2016.804] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
58 Chandra R, Balachandar N, Wang S, Reznik S, Zeh H, Porembka M. The changing face of gastric cancer: epidemiologic trends and advances in novel therapies. Cancer Gene Ther 2021;28:390-9. [PMID: 33009508 DOI: 10.1038/s41417-020-00234-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
59 Ku GY. Next generation sequencing in gastric or gastroesophageal adenocarcinoma. Transl Gastroenterol Hepatol 2020;5:56. [PMID: 33073051 DOI: 10.21037/tgh.2020.01.09] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
60 Gamboa AC, Winer JH. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer.Cancers (Basel). 2019;11:1662. [PMID: 31717799 DOI: 10.3390/cancers11111662] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
61 Kim YW, Eom BW, Kook MC, Kim HS, Kim MK, Hwang HL, Chandra V, Poojan S, Song Y, Koh JS, Bae CD, Ro J, Hong KM. Clinical implications of proliferation activity in T1 or T2 male gastric cancer patients. Exp Mol Med 2015;47:e193. [PMID: 26542785 DOI: 10.1038/emm.2015.79] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
62 Lichthardt S, Kerscher A, Dietz UA, Jurowich C, Kunzmann V, von Rahden BH, Germer CT, Wiegering A. Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer. BMC Cancer 2016;16:650. [PMID: 27538392 DOI: 10.1186/s12885-016-2708-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
63 Jiang Z, Sun Y, Zhang W, Cui C, Yang L, Zhou A. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study. Asia Pac J Clin Oncol 2020;16:180-6. [PMID: 32077628 DOI: 10.1111/ajco.13321] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
64 Tokunaga M, Sato Y, Nakagawa M, Aburatani T, Matsuyama T, Nakajima Y, Kinugasa Y. Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives. Surg Today. 2020;50:30-37. [PMID: 31612329 DOI: 10.1007/s00595-019-01896-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
65 Hur H, Paik MJ, Xuan Y, Nguyen DT, Ham IH, Yun J, Cho YK, Lee G, Han SU. Quantitative measurement of organic acids in tissues from gastric cancer patients indicates increased glucose metabolism in gastric cancer. PLoS One. 2014;9:e98581. [PMID: 24911788 DOI: 10.1371/journal.pone.0098581] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
66 Jain VK, Cunningham D, Rao S. Chemotherapy for operable gastric cancer: current perspectives. Indian J Surg Oncol. 2011;2:334-342. [PMID: 23204792 DOI: 10.1007/s13193-012-0139-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
67 Jin P, Ji X, Ma S, Kang W, Liu H, Li Y, Ma F, Hu H, Li W, Tian Y. Indications for adjuvant chemotherapy in patients with pT1N1M0 gastric cancer: a single-center experience. J Cancer Res Clin Oncol 2021;147:561-8. [PMID: 32772233 DOI: 10.1007/s00432-020-03355-y] [Reference Citation Analysis]
68 Kim SH, Lee HJ, Park JH, Choi JH, Park SH, Choe HN, Oh SY, Suh YS, Kong SH, Park DJ, Yang HK. Proposal of a New TNM Classification for Gastric Cancer: Focusing on pN3b and Cytology-Positive (CY1) Disease. J Gastric Cancer 2019;19:329-43. [PMID: 31598375 DOI: 10.5230/jgc.2019.19.e33] [Reference Citation Analysis]
69 Jin P, Liu H, Ma FH, Ma S, Li Y, Xiong JP, Kang WZ, Hu HT, Tian YT. Retrospective analysis of surgically treated pT4b gastric cancer with pancreatic head invasion . World J Clin Cases 2021; 9(29): 8718-8728 [PMID: 34734050 DOI: 10.12998/wjcc.v9.i29.8718] [Reference Citation Analysis]
70 Song S, Chie EK, Kim K, Lee HJ, Yang HK, Han SW, Oh DY, Im SA, Bang YJ, Ha SW. Postoperative chemoradiotherapy in high risk locally advanced gastric cancer. Radiat Oncol J 2012;30:213-7. [PMID: 23346541 DOI: 10.3857/roj.2012.30.4.213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
71 Chen S, Ou-Yang LY, Nie RC, Li YF, Xiang J, Zhou ZW, Chen YB, Peng JS. Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T3-4aN0M0 Gastric Cancer Patients after D2 Gastrectomy. Gastroenterol Res Pract 2017;2017:4928736. [PMID: 28331491 DOI: 10.1155/2017/4928736] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
72 Ma M, Xiao H, Li L, Yin X, Zhou H, Quan H, Ouyang Y, Huang G, Li X, Xiao H. Development and validation of a prognostic nomogram for predicting early recurrence after curative resection of stage II/III gastric cancer. World J Surg Oncol 2019;17:223. [PMID: 31856828 DOI: 10.1186/s12957-019-1750-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
73 Wang X, Liu Y, Niu Z, Fu R, Jia Y, Zhang L, Shao D, Du H, Hu Y, Xing X, Cheng X, Li L, Guo T, Li Z, Ji Q, Zhang L, Ji J. Prognostic value of a 25-gene assay in patients with gastric cancer after curative resection. Sci Rep 2017;7:7515. [PMID: 28790411 DOI: 10.1038/s41598-017-07604-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
74 Oba K, Paoletti X, Alberts S, Bang YJ, Benedetti J, Bleiberg H, Catalano P, Lordick F, Michiels S, Morita S. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst. 2013;105:1600-1607. [PMID: 24108812 DOI: 10.1093/jnci/djt270] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 10.8] [Reference Citation Analysis]
75 Zhang H, Wu J, Yuan J, Li H, Zhang Y, Wu W, Chen W, Wang C, Meng S, Chen S, Huo M, He Y, Zhang C. Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer. J Exp Clin Cancer Res 2021;40:260. [PMID: 34412665 DOI: 10.1186/s13046-021-02052-z] [Reference Citation Analysis]
76 Toneto MG, Viola L. CURRENT STATUS OF THE MULTIDISCIPLINARY TREATMENT OF GASTRIC ADENOCARCINOMA. Arq Bras Cir Dig 2018;31:e1373. [PMID: 29972401 DOI: 10.1590/0102-672020180001e1373] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
77 Ostwal V, Sahu A, Ramaswamy A, Sirohi B, Bose S, Talreja V, Goel M, Patkar S, Desouza A, Shrikhande SV. Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis. J Gastric Cancer 2017;17:21-32. [PMID: 28337360 DOI: 10.5230/jgc.2017.17.e3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
78 Yoshikawa T, Aoyama T, Sakamaki K, Oshima T, Lin J, Zhang S, Sapari NS, Soong R, Tan I, Chan XB, Bottomley D, Hewitt LC, Arai T, Teh BT, Epstein D, Ogata T, Kameda Y, Miyagi Y, Tsuburaya A, Morita S, Grabsch HI, Tan P. Comprehensive biomarker analyses identifies HER2, EGFR, MET RNA expression and thymidylate synthase 5'UTR SNP as predictors of benefit from S-1 adjuvant chemotherapy in Japanese patients with stage II/III gastric cancer. J Cancer 2019;10:5130-8. [PMID: 31602266 DOI: 10.7150/jca.34741] [Reference Citation Analysis]
79 Nilsson M. Postgastrectomy follow-up in the West: evidence base, guidelines, and daily practice. Gastric Cancer 2017;20:135-40. [PMID: 27718134 DOI: 10.1007/s10120-016-0654-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
80 van den Ende T, Ter Veer E, Machiels M, Mali RMA, Abe Nijenhuis FA, de Waal L, Laarman M, Gisbertz SS, Hulshof MCCM, van Oijen MGH, van Laarhoven HWM. The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis. Cancers (Basel) 2019;11:E80. [PMID: 30641964 DOI: 10.3390/cancers11010080] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
81 Batista TP, Martins MR. Lymph node dissection for gastric cancer: a critical review. Oncol Rev 2012;6:e12. [PMID: 25992202 DOI: 10.4081/oncol.2012.e12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
82 Kang WM, Meng QB, Yu JC, Ma ZQ, Li ZT. Factors associated with early recurrence after curative surgery for gastric cancer. World J Gastroenterol 2015; 21(19): 5934-5940 [PMID: 26019458 DOI: 10.3748/wjg.v21.i19.5934] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 39] [Article Influence: 6.5] [Reference Citation Analysis]
83 Farooq F, Zarrabi K, Sweeney K, Kim J, Bandovic J, Patel C, Choi M. Multiregion Comprehensive Genomic Profiling of a Gastric Mixed Neuroendocrine-Nonneuroendocrine Neoplasm with Trilineage Differentiation. J Gastric Cancer 2018;18:200-7. [PMID: 29984070 DOI: 10.5230/jgc.2018.18.e16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
84 Jomrich G, Schoppmann SF. Targeted therapy in gastric cancer. Eur Surg 2016;48:278-84. [PMID: 27795701 DOI: 10.1007/s10353-016-0389-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
85 Wang PX, Wang HJ, Liu JH, Qiu GL, Lu J, Fan L, Liao XH, Che XM. A nomogram combining plasma fibrinogen and systemic immune‑inflammation index predicts survival in patients with resectable gastric cancer. Sci Rep 2021;11:10301. [PMID: 33986408 DOI: 10.1038/s41598-021-89648-9] [Reference Citation Analysis]
86 Lieto E, Galizia G, Auricchio A, Cardella F, Mabilia A, Basile N, Del Sorbo G, Castellano P, Romano C, Orditura M, Napolitano V. Preoperative Neutrophil to Lymphocyte Ratio and Lymphocyte to Monocyte Ratio are Prognostic Factors in Gastric Cancers Undergoing Surgery. J Gastrointest Surg. 2017;21:1764-1774. [PMID: 28752404 DOI: 10.1007/s11605-017-3515-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
87 Taketa T, Sudo K, Wadhawa R, Blum MM, Ajani JA. Adjuvant therapy in gastric cancer: what is the optimal approach? Curr Oncol Rep. 2013;15:146-151. [PMID: 23355076 DOI: 10.1007/s11912-013-0298-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
88 Pectasides E, Chatzidakis I, Kotoula V, Koliou GA, Papadopoulou K, Giannoulatou E, Giannouzakos VG, Bobos M, Papavasileiou C, Chrisafi S, Florou A, Pectasides D, Fountzilas G. Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy. Cancer Genomics Proteomics 2020;17:277-90. [PMID: 32345669 DOI: 10.21873/cgp.20188] [Reference Citation Analysis]
89 Mingol F, Gallego J, Orduña A, Martinez-Blasco A, Sola-Vera J, Moya P, Morcillo MA, Ruiz JA, Calpena R, Lacueva FJ. Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction. BMC Surg 2015;15:66. [PMID: 25997454 DOI: 10.1186/s12893-015-0054-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
90 Liu GH, Liu YH, Yang Z, Zhu AL, Zhao CL. MicroRNA-524-5p suppresses the growth and invasive abilities of gastric cancer cells. Oncol Lett 2016;11:1926-32. [PMID: 26998102 DOI: 10.3892/ol.2016.4143] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
91 Nie R, Yuan S, Chen S, Chen X, Chen Y, Zhu B, Qiu H, Zhou Z, Peng J, Chen Y. Prognostic nutritional index is an independent prognostic factor for gastric cancer patients with peritoneal dissemination. Chin J Cancer Res. 2016;28:570-578. [PMID: 28174485 DOI: 10.21147/j.issn.1000-9604.2016.06.03] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
92 Kano M, Hayano K, Hayashi H, Hanari N, Gunji H, Toyozumi T, Murakami K, Uesato M, Ota S, Matsubara H. Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis. Ann Surg Oncol 2019;26:1805-13. [PMID: 30977014 DOI: 10.1245/s10434-019-07299-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
93 Xie D, Shen J, Liu L, Cao B, Wang Y, Qin J, Wu J, Yan Q, Hu Y, Yang C, Cao Z, Hu J, Yin P, Gong J. Complete mesogastric excision for locally advanced gastric cancer: short-term outcomes of a randomized clinical trial. Cell Rep Med 2021;2:100217. [PMID: 33763656 DOI: 10.1016/j.xcrm.2021.100217] [Reference Citation Analysis]
94 Cavaliere A, Merz V, Casalino S, Zecchetto C, Simionato F, Salt HL, Contarelli S, Santoro R, Melisi D. Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer. J Gastric Cancer 2019;19:375-92. [PMID: 31897341 DOI: 10.5230/jgc.2019.19.e39] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
95 Tomasello G, Valeri N, Ghidini M, Smyth EC, Liguigli W, Toppo L, Mattioli R, Curti A, Hahne JC, Negri FM. First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study. Oncotarget. 2017;8:111795-111806. [PMID: 29340092 DOI: 10.18632/oncotarget.22909] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
96 Di Bartolomeo M, Morano F, Raimondi A, Miceli R, Corallo S, Tamborini E, Perrone F, Antista M, Niger M, Pellegrinelli A, Randon G, Pagani F, Martinetti A, Fucà G, Pietrantonio F; ITACA-S study group. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. Oncologist 2020;25:e460-8. [PMID: 32162808 DOI: 10.1634/theoncologist.2019-0471] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
97 Kawaguchi Y, Akaike H, Shoda K, Furuya S, Hosomura N, Amemiya H, Kawaida H, Kono H, Ichikawa D. Is surgery the best treatment for elderly gastric cancer patients? World J Gastrointest Surg 2021; 13(11): 1351-1360 [DOI: 10.4240/wjgs.v13.i11.1351] [Reference Citation Analysis]
98 Sanjeevaiah A, Park H, Fangman B, Porembka M. Gastric Cancer with Radiographically Occult Metastatic Disease: Biology, Challenges, and Diagnostic Approaches. Cancers (Basel) 2020;12:E592. [PMID: 32150838 DOI: 10.3390/cancers12030592] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Yen CC, Shan YS, Chao YJ, Liao TK, Chen IS, Huang HY, Liu IT, Yen CJ. Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis. BMC Cancer 2021;21:796. [PMID: 34243732 DOI: 10.1186/s12885-021-08487-z] [Reference Citation Analysis]
100 Yu JI, Lim DH, Lee J, Kang WK, Park SH, Park JO, Park YS, Lim HY, Kim ST, Lee SJ, Kim S, Sohn TS, Lee JH, An JY, Choi MG, Bae JM, Yoo H, Kim K. Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols. Cancer Res Treat 2019;51:876-85. [PMID: 30282450 DOI: 10.4143/crt.2018.401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
101 Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, Lee KW, Kim EH, Yim SY, Lee SH, Cheong JH, Jeong W, Cho JY, Kim J, Chae J, Lee J, Kang WK, Kim S, Noh SH, Ajani JA, Lee JS. Clinical significance of four molecular subtypes of gastric cancer Identified by The Cancer Genome Atlas project. Clin Cancer Res. 2017;. [PMID: 28747339 DOI: 10.1158/1078-0432.ccr-16-2211] [Cited by in Crossref: 147] [Cited by in F6Publishing: 96] [Article Influence: 36.8] [Reference Citation Analysis]
102 Kang YK, Chang HM, Yook JH, Ryu MH, Park I, Min YJ, Zang DY, Kim GY, Yang DH, Jang SJ. Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201). Br J Cancer. 2013;108:1245-1251. [PMID: 23449357 DOI: 10.1038/bjc.2013.86] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
103 Chen ZD, Zhang PF, Xi HQ, Wei B, Chen L. AKT inhibits the phosphorylation level of H2A at Tyr57 via CK2α to promote the progression of gastric cancer. J Gastrointest Oncol 2021;12:1363-73. [PMID: 34532094 DOI: 10.21037/jgo-21-260] [Reference Citation Analysis]
104 Yang K, Choi YY, Zhang WH, Chen XZ, Song MK, Lee J, Zhang B, Chen ZX, Kim HI, Chen JP. Strategies to improve treatment outcome in gastric cancer: a retrospective analysis of patients from two high-volume hospitals in Korea and China. Oncotarget. 2016;7:44660-44675. [PMID: 27191995 DOI: 10.18632/oncotarget.9378] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
105 Aoyama T, Sato T, Maezawa Y, Kano K, Hayashi T, Yamada T, Yukawa N, Oshima T, Rino Y, Masuda M, Ogata T, Cho H, Yoshikawa T. Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer. Int J Clin Oncol 2017;22:476-83. [PMID: 28176023 DOI: 10.1007/s10147-017-1089-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
106 Mirza A, Pritchard S, Welch I. The postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomas. Int J Surg Oncol. 2013;2013:781742. [PMID: 24163764 DOI: 10.1155/2013/781742] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
107 Chang HR, Nam S, Lee J, Kim JH, Jung HR, Park HS, Park S, Ahn YZ, Huh I, Balch C, Ku JL, Powis G, Park T, Jeong JH, Kim YH. Systematic approach identifies RHOA as a potential biomarker therapeutic target for Asian gastric cancer. Oncotarget. 2016;7:81435-81451. [PMID: 27806312 DOI: 10.18632/oncotarget.12963] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
108 Wang L, Jiao Y, Jiao Y, Cao Y, Gu W. Gastric cancer drug trials - are women second class citizens? Nat Rev Clin Oncol 2014;11. [PMID: 24889767 DOI: 10.1038/nrclinonc.2013.231-c1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
109 Brind'Amour A, Gagné JP, Hogue JC, Poirier É. Impact of the introduction of formal D2 lymphadenectomy for gastric cancer in a Western setting. Can J Surg 2021;64:E119-26. [PMID: 33651574 DOI: 10.1503/cjs.019919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Nakamura N, Shiraiwa H, Haruna Y, Ichijima T, Takeda T, Hasegawa K, Kusumoto M, Yano Y. Effectiveness of protocol-based pharmacotherapy management collaboration between hospital and community pharmacists to address capecitabine-related hand-foot syndrome in cancer patients: a retrospective study. J Pharm Health Care Sci 2021;7:8. [PMID: 33641672 DOI: 10.1186/s40780-021-00191-1] [Reference Citation Analysis]
111 Duan S, Wang P, Liu F, Huang H, An W, Pan S, Wang X. Novel immune-risk score of gastric cancer: A molecular prediction model combining the value of immune-risk status and chemosensitivity. Cancer Med 2019;8:2675-85. [PMID: 30945466 DOI: 10.1002/cam4.2077] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
112 Quan R, Huang J, Chen H, Liao Y, Lv W, Chen N, Liu J, Zhang H, Xu D. Comparison of efficacy in adjuvant chemotherapy regimens in patients with radically resected gastric cancer : a propensity-matched analysis. Oncotarget 2016;7:76316-26. [PMID: 27602756 DOI: 10.18632/oncotarget.11783] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
113 Nakajima T, Fujii M. What make differences in the outcome of adjuvant treatments for resected gastric cancer? World J Gastroenterol 2014; 20(33): 11567-11573 [PMID: 25206264 DOI: 10.3748/wjg.v20.i33.11567] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
114 Miyata Y, Kogure R, Nakazawa A, Nagata R, Mitsui T, Ninomiya R, Komagome M, Maki A, Kawarabayashi N, Beck Y. The Efficacy of S-1 as Adjuvant Chemotherapy for Resected Biliary Tract Carcinoma: A Propensity Score-Matching Analysis. J Clin Med 2021;10:925. [PMID: 33804297 DOI: 10.3390/jcm10050925] [Reference Citation Analysis]
115 Wang P, Zhou H, Han G, Ni Q, Dai S, Huang J, Dai C, Yu L. Assessment of the value of adjuvant radiotherapy for treatment of gastric adenocarcinoma based on pattern of post-surgical progression. World J Surg Oncol 2021;19:205. [PMID: 34238296 DOI: 10.1186/s12957-021-02304-4] [Reference Citation Analysis]
116 Sugita S, Kinoshita T, Kuwata T, Tokunaga M, Kaito A, Watanabe M, Tonouchi A, Sato R, Nagino M. Long-term oncological outcomes of laparoscopic versus open transhiatal resection for patients with Siewert type II adenocarcinoma of the esophagogastric junction. Surg Endosc 2021;35:340-8. [PMID: 32025923 DOI: 10.1007/s00464-020-07406-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
117 Chang AY, Foo KF, Koo WH, Ong S, So J, Tan D, Lim KH. Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer. BMJ Open Gastroenterol 2016;3:e000095. [PMID: 27648294 DOI: 10.1136/bmjgast-2016-000095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
118 Jabo B, Selleck MJ, Morgan JW, Lum SS, Bahjri K, Aljehani M, Garberoglio CA, Reeves ME, Namm JP, Solomon NL, Luca F, Yang G, Senthil M. Role of lymph node ratio in selection of adjuvant treatment (chemotherapy vs. chemoradiation) in patients with resected gastric cancer. J Gastrointest Oncol 2018;9:708-17. [PMID: 30151267 DOI: 10.21037/jgo.2018.05.12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
119 Hwang JE, Kim H, Shim HJ, Bae WK, Hwang EC, Jeong O, Ryu SY, Park YK, Cho SH, Chung IJ. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer. J Cancer Res Clin Oncol 2019;145:2157-66. [PMID: 31273512 DOI: 10.1007/s00432-019-02963-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
120 Liao YQ, Liao YL, Li J, Peng LX, Wan YY, Zhong R. Polymorphism in miR-146a associated with clinical characteristics and outcomes in gastric cancer patients treated with adjuvant oxaliplatin and fluoropyrimidines. Onco Targets Ther 2015;8:2627-33. [PMID: 26396533 DOI: 10.2147/OTT.S89635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
121 Krasniqi E, Pellicori S, Formica V. Emerging role of S-1 in gastric cancer. Indian J Med Paediatr Oncol 2015;36:219-28. [PMID: 26811591 DOI: 10.4103/0971-5851.171542] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
122 Liu Y, Feng Y, Gao Y, Hou R. Clinical benefits of combined chemotherapy with S-1, oxaliplatin, and docetaxel in advanced gastric cancer patients with palliative surgery. Onco Targets Ther 2016;9:1269-73. [PMID: 27095004 DOI: 10.2147/OTT.S99684] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
123 Zhu R, Liu F, Grisotti G, Perez-Irizarry J, Salem RR, Cha CH, Johung KL, Boffa DJ, Zhang Y, Khan SA. Clinical impact of underutilization of adjuvant therapy in node positive gastric adenocarcinoma. J Gastrointest Oncol 2018;9:517-26. [PMID: 29998017 DOI: 10.21037/jgo.2018.03.05] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
124 Ding P, Zheng C, Cao G, Gao Z, Lei Y, Deng P, Hou B, Li K. Combination of preoperative plasma fibrinogen and AJCC staging improves the accuracy of survival prediction for patients with stage I-II gastric cancer after curative gastrectomy. Cancer Med 2019;8:2919-29. [PMID: 31050218 DOI: 10.1002/cam4.2086] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
125 Muti HS, Heij LR, Keller G, Kohlruss M, Langer R, Dislich B, Cheong JH, Kim YW, Kim H, Kook MC, Cunningham D, Allum WH, Langley RE, Nankivell MG, Quirke P, Hayden JD, West NP, Irvine AJ, Yoshikawa T, Oshima T, Huss R, Grosser B, Roviello F, d'Ignazio A, Quaas A, Alakus H, Tan X, Pearson AT, Luedde T, Ebert MP, Jäger D, Trautwein C, Gaisa NT, Grabsch HI, Kather JN. Development and validation of deep learning classifiers to detect Epstein-Barr virus and microsatellite instability status in gastric cancer: a retrospective multicentre cohort study. Lancet Digit Health 2021;3:e654-64. [PMID: 34417147 DOI: 10.1016/S2589-7500(21)00133-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
126 Boda-Heggemann J, Weiss C, Schneider V, Hofheinz RD, Haneder S, Michaely H, Wertz H, Ronellenfitsch U, Hochhaus A, Wenz F, Lohr F. Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer. Strahlenther Onkol 2013;189:417-23. [PMID: 23558673 DOI: 10.1007/s00066-013-0309-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
127 Eom BW, Joo J, Kim S, Shin A, Yang HR, Park J, Choi IJ, Kim YW, Kim J, Nam BH. Prediction Model for Gastric Cancer Incidence in Korean Population. PLoS One 2015;10:e0132613. [PMID: 26186332 DOI: 10.1371/journal.pone.0132613] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
128 Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. J Gastric Cancer 2019;19:1-48. [PMID: 30944757 DOI: 10.5230/jgc.2019.19.e8] [Cited by in Crossref: 103] [Cited by in F6Publishing: 102] [Article Influence: 51.5] [Reference Citation Analysis]
129 Zhao C, Feng Z, He H, Zang D, Du H, Huang H, Du Y, He J, Zhou Y, Nie Y. Protein expression-based classification of gastric cancer by immunohistochemistry of tissue microarray. PLoS One 2020;15:e0238836. [PMID: 33095797 DOI: 10.1371/journal.pone.0238836] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
130 Gu L, Wang M, Cui X, Mo J, Yuan L, Mao F, Zhang K, Ng DM, Chen P, Wang D. Clinical significance of peripheral blood-derived inflammation markers in advanced gastric cancer after radical resection. BMC Surg 2020;20:219. [PMID: 33008382 DOI: 10.1186/s12893-020-00884-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
131 Liu X, Jin J, Cai H, Huang H, Zhao G, Zhou Y, Wu J, Du C, Long Z, Fang Y, Ma M, Li G, Zhou M, Yin J, Zhu X, Zhu J, Sheng W, Huang D, Zhu H, Zhang Z, Lu Q, Xie L, Zhang Z, Wang Y. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT. BMC Cancer 2019;19:606. [PMID: 31221115 DOI: 10.1186/s12885-019-5728-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
132 Yen HH, Chen CN, Yeh CC, Lai IR. Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience. World J Surg Oncol 2021;19:124. [PMID: 33865416 DOI: 10.1186/s12957-021-02233-2] [Reference Citation Analysis]
133 Chen X, Eads JR, Ammori JB, Kumar AM, Biswas T, Dorth JA. Adjuvant and neoadjuvant options in resectable gastric cancer: is there an optimal treatment approach? Curr Oncol Rep 2015;17:18. [PMID: 25708803 DOI: 10.1007/s11912-015-0442-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
134 Jin Y, Qiu MZ, Wang DS, Zhang DS, Ren C, Bai L, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH. Adjuvant chemotherapy for elderly patients with gastric cancer after D2 gastrectomy. PLoS One 2013;8:e53149. [PMID: 23359796 DOI: 10.1371/journal.pone.0053149] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
135 Lin JX, Lin JP, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu R, Zheng CH, Huang CM, Li P. Prognostic importance of the preoperative modified systemic inflammation score for patients with gastric cancer. Gastric Cancer. 2019;22:403-412. [PMID: 29982861 DOI: 10.1007/s10120-018-0854-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
136 Yang Y, Yin X, Sheng L, Xu S, Dong L, Liu L. Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated Meta-analysis. Sci Rep 2015;5:12850. [PMID: 26242393 DOI: 10.1038/srep12850] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
137 Sawayama H, Iwatsuki M, Kuroda D, Toihata T, Uchihara T, Koga Y, Yagi T, Kiyozumi Y, Eto T, Hiyoshi Y, Ishimoto T, Baba Y, Miyamoto Y, Yoshida N, Baba H. The association of the lymph node ratio and serum carbohydrate antigen 19-9 with early recurrence after curative gastrectomy for gastric cancer. Surg Today 2018;48:994-1003. [PMID: 29926189 DOI: 10.1007/s00595-018-1684-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
138 Rivera F, Romero C, Jimenez-Fonseca P, Izquierdo-Manuel M, Salud A, Martínez E, Jorge M, Arrazubi V, Méndez JC, García-Alfonso P, Reboredo M, Barriuso J, Muñoz-Unceta N, Jimeno R, López C. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. Cancer Chemother Pharmacol 2019;83:1175-81. [PMID: 30927036 DOI: 10.1007/s00280-019-03820-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
139 Yu P, Du Y, Cheng X, Yu Q, Huang L, Dong R. Expression of multidrug resistance-associated proteins and their relation to postoperative individualized chemotherapy in gastric cancer. World J Surg Oncol. 2014;12:307. [PMID: 25304659 DOI: 10.1186/1477-7819-12-307] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
140 Jácome AA, Sankarankutty AK, dos Santos JS. Adjuvant therapy for gastric cancer: What have we learned since INT0116? World J Gastroenterol 2015; 21(13): 3850-3859 [PMID: 25852269 DOI: 10.3748/wjg.v21.i13.3850] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
141 Huang SM, Chen YC, Chen WY, Yang LY, Tsan DL, Tsang NM, Yap WK, Tsai CS, Leung WM, Hong JH, Chang JT, Yeh TS, Wu TH, Chen YC, Lin YH, Huang BS. Optimal Timing for Postsurgical Adjuvant Therapy in Patients with Gastric Cancer: A Propensity Score Matching Study. J Cancer 2019;10:332-40. [PMID: 30719127 DOI: 10.7150/jca.27753] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
142 Cho JH, Lim JY, Cho JY. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. PLoS One 2017;12:e0186362. [PMID: 29040299 DOI: 10.1371/journal.pone.0186362] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
143 Chen Y, Li C, Du Y, Xu Q, Ying J, Luo C. Prognostic and predictive value of metastatic lymph node ratio in stage III gastric cancer after D2 nodal dissection. Oncotarget 2017;8:70841-6. [PMID: 29050324 DOI: 10.18632/oncotarget.19998] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
144 Zhang P, Luo HS, Li M, Tan SY. Artesunate inhibits the growth and induces apoptosis of human gastric cancer cells by downregulating COX-2. Onco Targets Ther. 2015;8:845-854. [PMID: 25945055 DOI: 10.2147/ott.s81041] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
145 Mulder KE, Ahmed S, Davies JD, Doll CM, Dowden S, Gill S, Gordon V, Hebbard P, Lim H, McFadden A, McGhie JP, Park J, Wong R. Report from the 17th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Edmonton, Alberta; 11-12 September 2015. Curr Oncol. 2016;23:425-434. [PMID: 28050139 DOI: 10.3747/co.23.3384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
146 Li M, Zhao Y, Zhao E, Wang K, Lu W, Yuan L. Predictive Value of Two Polymorphisms of ERCC2, rs13181 and rs1799793, in Clinical Outcomes of Chemotherapy in Gastric Cancer Patients: A Meta-Analysis. Dis Markers 2018;2018:3947626. [PMID: 30581498 DOI: 10.1155/2018/3947626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
147 Klempner SJ, Wu W, Mehta P, Schrock AB, Chao J, Ali SM. Genomic Profiling to Expand Management Options for Locally Advanced Esophagogastric Cancers: A Proof of Principle Case. JCO Precis Oncol 2017;1:PO. [PMID: 32913963 DOI: 10.1200/PO.17.00166] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
148 Koerfer J, Kallendrusch S, Merz F, Wittekind C, Kubick C, Kassahun WT, Schumacher G, Moebius C, Gaßler N, Schopow N, Geister D, Wiechmann V, Weimann A, Eckmann C, Aigner A, Bechmann I, Lordick F. Organotypic slice cultures of human gastric and esophagogastric junction cancer. Cancer Med 2016;5:1444-53. [PMID: 27073068 DOI: 10.1002/cam4.720] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
149 Petrelli F, Barni S, Cascinu S, Zaniboni A. Gastric cancer: toward a cisplatin-free disease? J Gastrointest Oncol 2014;5:318-22. [PMID: 25083304 DOI: 10.3978/j.issn.2078-6891.2014.022] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
150 Liu YY, Liu YW, Chen YY, Wang SH, Chuah SK, Huang GK, Chen YH. The efficacy and toxicity of adjuvant S-1 schedule with 2-week administration followed by 1-week rest in gastric cancer patients. J Gastrointest Oncol 2021;12:297-306. [PMID: 34012627 DOI: 10.21037/jgo-20-477] [Reference Citation Analysis]
151 Tan C, Peng L, Zeng X, Li J, Wan X, Chen G, Yi L, Luo X, Zhao Z. Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China. PLoS One 2013;8:e83396. [PMID: 24340099 DOI: 10.1371/journal.pone.0083396] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
152 Chou WC, Chang CL, Liu KH, Hsu JT, Cheng WH, Hsu HC, Shen WC, Hung YS, Chen JS. Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment. World J Surg Oncol 2013;11:287. [PMID: 24180462 DOI: 10.1186/1477-7819-11-287] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
153 Shin SJ, Park S, Kim MH, Nam CM, Kim H, Choi YY, Jung MK, Choi HJ, Rha SY, Chung HC. Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer. Oncologist 2019;24:e1108-14. [PMID: 31015316 DOI: 10.1634/theoncologist.2018-0896] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
154 Yamada T, Yoshikawa T, Taguri M, Hayashi T, Aoyama T, Sue-Ling HM, Bonam K, Hayden JD, Grabsch HI. The survival difference between gastric cancer patients from the UK and Japan remains after weighted propensity score analysis considering all background factors. Gastric Cancer 2016;19:479-89. [PMID: 25761964 DOI: 10.1007/s10120-015-0480-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
155 Moorcraft SY, Smyth EC, Cunningham D. Adjuvant or neoadjuvant therapy for operable esophagogastric cancer? Gastric Cancer 2015;18:1-10. [PMID: 24638977 DOI: 10.1007/s10120-014-0356-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
156 Lee IS, Sahu D, Hur H, Yook JH, Kim BS, Goel A. Discovery and validation of an expression signature for recurrence prediction in high-risk diffuse-type gastric cancer. Gastric Cancer 2021;24:655-65. [PMID: 33523340 DOI: 10.1007/s10120-021-01155-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, Lieto E, Ciardiello F, De Vita F. Treatment of gastric cancer. World J Gastroenterol 2014; 20(7): 1635-1649 [PMID: 24587643 DOI: 10.3748/wjg.v20.i7.1635] [Cited by in CrossRef: 323] [Cited by in F6Publishing: 313] [Article Influence: 46.1] [Reference Citation Analysis]
158 Ge J, Liu T, Lei T, Li X, Song K, Azizi S, Liu H, Tang M. Retrospective Cohort Study of Intraoperative Administration of Sustained-Release 5-Fluorouracil Implants in Advanced Gastric Cancer Patients. Front Pharmacol 2021;12:659258. [PMID: 33927633 DOI: 10.3389/fphar.2021.659258] [Reference Citation Analysis]
159 Wang H, Wu X, Chen Y. Stromal-Immune Score-Based Gene Signature: A Prognosis Stratification Tool in Gastric Cancer. Front Oncol 2019;9:1212. [PMID: 31781506 DOI: 10.3389/fonc.2019.01212] [Cited by in Crossref: 39] [Cited by in F6Publishing: 48] [Article Influence: 19.5] [Reference Citation Analysis]
160 Wang QW, Zhang XT, Lu M, Shen L. Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer. World J Gastrointest Oncol 2018; 10(1): 31-39 [PMID: 29375746 DOI: 10.4251/wjgo.v10.i1.31] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
161 Xu W, Wang L, Yan C, He C, Lu S, Ni Z, Hua Z, Zhu Z, Sah BK, Yang Z, Zheng Y, Feng R, Li C, Yao X, Chen M, Liu W, Yan M, Zhu Z. Neoadjuvant Chemotherapy Versus Direct Surgery for Locally Advanced Gastric Cancer With Serosal Invasion (cT4NxM0): A Propensity Score-Matched Analysis. Front Oncol 2021;11:718556. [PMID: 34497768 DOI: 10.3389/fonc.2021.718556] [Reference Citation Analysis]
162 Peng C, Liu J, Yang G, Li Y. The tumor-stromal ratio as a strong prognosticator for advanced gastric cancer patients: proposal of a new TSNM staging system. J Gastroenterol 2018;53:606-17. [PMID: 28815347 DOI: 10.1007/s00535-017-1379-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
163 Gunturu KS, Woo Y, Beaubier N, Remotti HE, Saif MW. Gastric cancer and trastuzumab: first biologic therapy in gastric cancer. Ther Adv Med Oncol. 2013;5:143-151. [PMID: 23450234 DOI: 10.1177/1758834012469429] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 5.9] [Reference Citation Analysis]
164 Guo J, Chen S, Chen Y, Li S, Xu D. Combination of CRP and NLR: a better predictor of postoperative survival in patients with gastric cancer. Cancer Manag Res 2018;10:315-21. [PMID: 29491721 DOI: 10.2147/CMAR.S156071] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
165 Ma L, Wang X, Lan F, Yu Y, Ouyang X, Liu W, Xie F, Huang Q. Prognostic value of differential CCND1 expression in patients with resected gastric adenocarcinoma. Med Oncol. 2015;32:338. [PMID: 25452171 DOI: 10.1007/s12032-014-0338-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
166 Nie RC, Yuan SQ, Chen S, Yan SM, Chen YM, Chen XJ, Chen GM, Zhou ZW, Chen YB, Li YF. Bursectomy for advanced gastric cancer: an update meta-analysis. World J Surg Oncol 2018;16:66. [PMID: 29592807 DOI: 10.1186/s12957-018-1354-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
167 Zurlo IV, Schino M, Strippoli A, Calegari MA, Cocomazzi A, Cassano A, Pozzo C, Di Salvatore M, Ricci R, Barone C, Bria E, Tortora G, Larocca LM, Basso M, Martini M. Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. Cancer Immunol Immunother 2021. [PMID: 34009410 DOI: 10.1007/s00262-021-02960-1] [Reference Citation Analysis]
168 Zangouei AS, Moghbeli M. MicroRNAs as the critical regulators of cisplatin resistance in gastric tumor cells. Genes Environ 2021;43:21. [PMID: 34099061 DOI: 10.1186/s41021-021-00192-4] [Reference Citation Analysis]
169 Seol SY, Kim C, Lim JY, Yoon SO, Hong SW, Kim JW, Choi SH, Cho JY. Overexpression of Endoplasmic Reticulum Oxidoreductin 1-α (ERO1L) Is Associated with Poor Prognosis of Gastric Cancer. Cancer Res Treat 2016;48:1196-209. [PMID: 26987398 DOI: 10.4143/crt.2015.189] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
170 Jácome AA, Wohnrath DR, Scapulatempo Neto C, Fregnani JH, Quinto AL, Oliveira AT, Vazquez VL, Fava G, Martinez EZ, Santos JS. Effect of adjuvant chemoradiotherapy on overall survival of gastric cancer patients submitted to D2 lymphadenectomy. Gastric Cancer. 2013;16:233-238. [PMID: 22740060 DOI: 10.1007/s10120-012-0171-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
171 Fei Y, Cao Y, Gu Y, Fang H, Chen Y, Wang J, Liu X, Lv K, He X, Lin C, Liu H, Li H, He H, Li R, Zhang H, Zhang W. Intratumoral Foxp3+RORγt+ T cell infiltration determines poor prognosis and immunoevasive contexture in gastric cancer patients. Cancer Immunol Immunother 2021. [PMID: 33978826 DOI: 10.1007/s00262-021-02950-3] [Reference Citation Analysis]
172 Fukagawa T, Katai H, Mizusawa J, Nakamura K, Sano T, Terashima M, Ito S, Yoshikawa T, Fukushima N, Kawachi Y, Kinoshita T, Kimura Y, Yabusaki H, Nishida Y, Iwasaki Y, Lee SW, Yasuda T, Sasako M;  Stomach Cancer Study Group of the Japan Clinical Oncology Group. A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). Gastric Cancer. 2018;21:68-73. [PMID: 28194522 DOI: 10.1007/s10120-017-0701-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 11.8] [Reference Citation Analysis]
173 Fujitani K, Tamura S, Kimura Y, Tsuji T, Matsuyama J, Iijima S, Imamura H, Inoue K, Kobayashi K, Kurokawa Y. Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy. Gastric Cancer. 2013;Jun 5; Epub ahead of print. [PMID: 23736741 DOI: 10.1007/s10120-013-0273-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
174 Arrington AK, Nelson R, Patel SS, Luu C, Ko M, Garcia-Aguilar J, Kim J. Timing of chemotherapy and survival in patients with resectable gastric adenocarcinoma. World J Gastrointest Surg 2013; 5(12): 321-328 [PMID: 24392183 DOI: 10.4240/wjgs.v5.i12.321] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
175 Xue K, Ying X, Bu Z, Wu A, Li Z, Tang L, Zhang L, Zhang Y, Li Z, Ji J. Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II<b>-</b>III randomized trial. Chin J Cancer Res. 2018;30:516-525. [PMID: 30510363 DOI: 10.21147/j.issn.1000-9604.2018.05.05] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
176 Zhu L, Yu Q, Mercante DE. A Bayesian Sequential Design for Clinical Trials with Time-to-Event Outcomes. Stat Biopharm Res 2019;11:387-97. [PMID: 32226580 DOI: 10.1080/19466315.2019.1629996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
177 Petrillo A, Smyth EC. Biomarkers for Precision Treatment in Gastric Cancer. Visc Med 2020;36:364-72. [PMID: 33178733 DOI: 10.1159/000510489] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
178 Xu AM, Huang L, Liu W, Gao S, Han WX, Wei ZJ. Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9:e86941. [PMID: 24497999 DOI: 10.1371/journal.pone.0086941] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
179 Zhang X, Jiang LP, Yin Y, Wang YD. XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis. Tumour Biol 2014;35:5637-45. [PMID: 24590266 DOI: 10.1007/s13277-014-1746-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
180 Selby LV, Vertosick EA, Sjoberg DD, Schattner MA, Janjigian YY, Brennan MF, Coit DG, Strong VE. Morbidity after Total Gastrectomy: Analysis of 238 Patients. J Am Coll Surg 2015;220:863-871.e2. [PMID: 25842172 DOI: 10.1016/j.jamcollsurg.2015.01.058] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
181 Tanigawa N, Yamaue H, Ohyama S, Sakuramoto S, Inada T, Kodera Y, Kitagawa Y, Omura K, Terashima M, Sakata Y, Nashimoto A, Yamaguchi T, Chin K, Nomura E, Lee SW, Takeuchi M, Fujii M, Nakajima T. Exploratory phase II trial in a multicenter setting to evaluate the clinical value of a chemosensitivity test in patients with gastric cancer (JACCRO-GC 04, Kubota memorial trial). Gastric Cancer 2016;19:350-60. [PMID: 26385385 DOI: 10.1007/s10120-015-0506-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
182 Huang ZN, Ma Y, Chen QY, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Lu J, Cao LL, Lin M, Tu RH, Lin JL, Zheng HL, Huang CM. Potential survival benefits of open over laparoscopic radical gastrectomy for gastric cancer patients beyond three years after surgery: result from multicenter in-depth analysis based on propensity matching. Surg Endosc 2021. [PMID: 34085095 DOI: 10.1007/s00464-021-08430-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
183 Sun M, Qiu J, Zhai H, Wang Y, Ma P, Li M, Chen B. Prognostic Implications of Novel Gene Signatures in Gastric Cancer Microenvironment. Med Sci Monit 2020;26:e924604. [PMID: 32740646 DOI: 10.12659/MSM.924604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
184 Pepek JM, Chino JP, Willett CG, Palta M, Blazer Iii DG, Tyler DS, Uronis HE, Czito BG. Preoperative chemoradiotherapy for locally advanced gastric cancer. Radiat Oncol 2013;8:6. [PMID: 23286735 DOI: 10.1186/1748-717X-8-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
185 Jiang Y, Li T, Liang X, Hu Y, Huang L, Liao Z, Zhao L, Han Z, Zhu S, Wang M, Xu Y, Qi X, Liu H, Yang Y, Yu J, Liu W, Cai S, Li G. Association of Adjuvant Chemotherapy With Survival in Patients With Stage II or III Gastric Cancer. JAMA Surg 2017;152:e171087. [PMID: 28538950 DOI: 10.1001/jamasurg.2017.1087] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
186 Kim JY, Chung WS, Lee HJ, An JH, Son JS. Usefulness of histologic differences and perivascular infiltration for preoperative T staging of advanced gastric cancer using computed tomography. Jpn J Radiol. 2019;37:817-825. [PMID: 31625013 DOI: 10.1007/s11604-019-00887-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
187 Mawalla B, Yuan X, Luo X, Chalya PL. Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials. BMC Res Notes 2018;11:21. [PMID: 29329598 DOI: 10.1186/s13104-018-3137-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
188 Kim MH, Zhang X, Jung M, Jung I, Park HS, Beom SH, Kim HS, Rha SY, Kim H, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Noh SH, Chung HC. Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial. Cancer Res Treat 2019;51:819-31. [PMID: 30282452 DOI: 10.4143/crt.2018.331] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
189 Kondoh C, Shitara K, Nomura M, Takahari D, Ura T, Tachibana H, Tomita N, Kodaira T, Muro K. Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study. BMC Palliat Care 2015;14:37. [PMID: 26238344 DOI: 10.1186/s12904-015-0034-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
190 Kim HS, Kim JH, Kim JW, Kim BC. Chemotherapy in Elderly Patients with Gastric Cancer. J Cancer 2016;7:88-94. [PMID: 26722364 DOI: 10.7150/jca.13248] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
191 Saito H, Murakami Y, Miyatani K, Kuroda H, Matsunaga T, Fukumoto Y, Osaki T, Ikeguchi M. Predictive factors for recurrence in T2N0 and T3N0 gastric cancer patients. Langenbecks Arch Surg 2016;401:823-8. [PMID: 27460840 DOI: 10.1007/s00423-016-1480-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
192 Sawazaki S, Oshima T, Sakamaki K, Aoyama T, Sato T, Shiozawa M, Yoshikawa T, Rino Y, Imada T, Masuda M. Clinical Significance of Tensin 4 Gene Expression in Patients with Gastric Cancer. In Vivo 2017;31:1065-71. [PMID: 29102927 DOI: 10.21873/invivo.11171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
193 Zhou YJ, Zhu GQ, Lu XF, Zheng KI, Wang QW, Chen JN, Zhang QW, Yan FR, Li XB. Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications. Cancer Immunol Immunother 2020;69:1057-69. [PMID: 32100076 DOI: 10.1007/s00262-020-02525-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
194 Nakamura K, Kuwata T, Shimoda T, Mizusawa J, Katayama H, Kushima R, Taniguchi H, Sano T, Sasako M, Fukuda H. Determination of the optimal cutoff percentage of residual tumors to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-A). Gastric Cancer. 2015;18:597-604. [PMID: 24968818 DOI: 10.1007/s10120-014-0401-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
195 Kodera Y, Fujitani K, Fukushima N, Ito S, Muro K, Ohashi N, Yoshikawa T, Kobayashi D, Tanaka C, Fujiwara M. Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer. 2014;17:206-212. [PMID: 24022130 DOI: 10.1007/s10120-013-0299-x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 9.0] [Reference Citation Analysis]
196 Smyth EC, Cunningham D. Operable gastro-oesophageal junctional adenocarcinoma: Where to next? World J Gastrointest Oncol 2014; 6(6): 145-155 [PMID: 24936225 DOI: 10.4251/wjgo.v6.i6.145] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
197 Song JH, Choi YY, An JY, Kim DW, Hyung WJ, Noh SH. Short-Term Outcomes of Laparoscopic Total Gastrectomy Performed by a Single Surgeon Experienced in Open Gastrectomy: Review of Initial Experience. J Gastric Cancer 2015;15:159-66. [PMID: 26468413 DOI: 10.5230/jgc.2015.15.3.159] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
198 Yin X, Fang T, Wang Y, Li C, Wang Y, Zhang D, Xue Y. Efficacy of Postoperative FOLFOX Versus XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Platelet-Lymphocyte Ratio in Patients Receiving XELOX. Front Oncol 2020;10:584772. [PMID: 33425738 DOI: 10.3389/fonc.2020.584772] [Reference Citation Analysis]
199 Mrena J, Mattila A, Böhm J, Jantunen I, Kellokumpu I. Surgical care quality and oncologic outcome after D2 gastrectomy for gastric cancer. World J Gastroenterol 2015; 21(47): 13294-13301 [PMID: 26715812 DOI: 10.3748/wjg.v21.i47.13294] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
200 Yu R, Li Z, Zhang C, Song H, Deng M, Sun L, Xu L, Che X, Hu X, Qu X, Liu Y, Zhang Y. Elevated limb-bud and heart development (LBH) expression indicates poor prognosis and promotes gastric cancer cell proliferation and invasion via upregulating Integrin/FAK/Akt pathway. PeerJ 2019;7:e6885. [PMID: 31119084 DOI: 10.7717/peerj.6885] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
201 Thomson IG, Gotley DC, Barbour AP, Martin I, Jayasuria N, Thomas J, Smithers BM. Treatment results of curative gastric resection from a specialist Australian unit: low volume with satisfactory outcomes. Gastric Cancer. 2014;17:152-160. [PMID: 23474836 DOI: 10.1007/s10120-013-0240-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
202 Kim KW, Lee K, Lee JB, Park T, Khang S, Jeong H, Ko CS, Yook JH, Kim BS, Lee IS. Preoperative nutritional risk index and postoperative one-year skeletal muscle loss can predict the prognosis of patients with gastric adenocarcinoma: a registry-based study. BMC Cancer 2021;21:157. [PMID: 33579228 DOI: 10.1186/s12885-021-07885-7] [Reference Citation Analysis]
203 Gervaso L, Pellicori S, Cella CA, Bagnardi V, Lordick F, Fazio N. Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal. Ther Adv Med Oncol 2021;13:17588359211029559. [PMID: 34484429 DOI: 10.1177/17588359211029559] [Reference Citation Analysis]
204 Li W, Zhang L, Tian C, Song H, Fang M, Hu C, Zang Y, Cao Y, Dai S, Wang F, Dong D, Wang R, Tian J. Prognostic value of computed tomography radiomics features in patients with gastric cancer following curative resection. Eur Radiol. 2019;29:3079-3089. [PMID: 30519931 DOI: 10.1007/s00330-018-5861-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
205 Cheng X, Yu S, Wang Y, Cui Y, Li W, Yu Y, Tang C, Jiang H, Ji Y, Sun Y, Wang X, Shen Z, Liu F, Liu TS. The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study. Gastric Cancer 2019;22:587-97. [PMID: 30426294 DOI: 10.1007/s10120-018-0895-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
206 Zeng Z, Xie D, Gong J. Genome-wide identification of CpG island methylator phenotype related gene signature as a novel prognostic biomarker of gastric cancer. PeerJ 2020;8:e9624. [PMID: 32821544 DOI: 10.7717/peerj.9624] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
207 Tan Y, Chen Q, Xing Y, Zhang C, Pan S, An W, Xu H. High expression of COL5A2, a member of COL5 family, indicates the poor survival and facilitates cell migration in gastric cancer. Biosci Rep 2021;41:BSR20204293. [PMID: 33739392 DOI: 10.1042/BSR20204293] [Reference Citation Analysis]
208 Lin JX, Wang ZK, Huang YQ, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Zheng HL, Zheng CH, Huang CM, Li P. Clinical Relevance of Splenic Hilar Lymph Node Dissection for Proximal Gastric Cancer: A Propensity Score-Matching Case-Control Study. Ann Surg Oncol 2021. [PMID: 33768400 DOI: 10.1245/s10434-021-09830-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
209 Chen QY, Zhong Q, Zhou JF, Qiu XT, Dang XY, Cai LS, Su GQ, Xu DB, Liu ZY, Li P, Guo KQ, Xie JW, Chen QX, Wang JB, Li TW, Lin JX, Lin SM, Lu J, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Lin W, He QL, Zheng CH, Huang CM. Development and External Validation of Web-Based Models to Predict the Prognosis of Remnant Gastric Cancer after Surgery: A Multicenter Study. J Oncol. 2019;2019:6012826. [PMID: 31093283 DOI: 10.1155/2019/6012826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
210 Huang YY, Yang Q, Zhou SW, Wei Y, Chen YX, Xie DR, Zhang B. Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 Lymphadenectomy: a meta-analysis. PLoS One. 2013;8:e68939. [PMID: 23874819 DOI: 10.1371/journal.pone.0068939] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
211 Jung M, Yang Y, McCloskey JE, Zaman M, Vedvyas Y, Zhang X, Stefanova D, Gray KD, Min IM, Zarnegar R, Choi YY, Cheong JH, Noh SH, Rha SY, Chung HC, Jin MM. Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. Mol Ther Oncolytics 2020;18:587-601. [PMID: 32995483 DOI: 10.1016/j.omto.2020.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
212 Li YF, Nie RC, Wu T, Li SM, Chen S, Wang W, Chen XJ, Chen GM, Chen YB, Zhou ZW, Yuan SQ. Prognostic Value of the Nutritional Risk Screening 2002 Scale in Metastatic Gastric Cancer: A Large-Scale Cohort Study. J Cancer 2019;10:112-9. [PMID: 30662531 DOI: 10.7150/jca.27729] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
213 Seo SH, Kim SE, Kang YK, Ryoo BY, Ryu MH, Jeong JH, Kang SS, Yang M, Lee JE, Sung MK. Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients. BMC Cancer 2016;16:900. [PMID: 27863481 DOI: 10.1186/s12885-016-2934-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
214 Ji X, Pan C, Li X, Gao Y, Xia L, Quan X, Lv J, Wang R. Trametes robiniophila may induce apoptosis and inhibit MMPs expression in the human gastric carcinoma cell line MKN-45. Oncol Lett 2017;13:841-6. [PMID: 28356967 DOI: 10.3892/ol.2016.5517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
215 Zhang L, Li W, Lyu X, Song Y, Mao Y, Wang S, Huang J. Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. Chin J Cancer Res 2017;29:149-55. [PMID: 28536494 DOI: 10.21147/j.issn.1000-9604.2017.02.08] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
216 Peixoto RD, Rocha-Filho DR, Weschenfelder RF, Rego JFM, Riechelmann R, Coutinho AK, Fernandes GS, Jacome AA, Andrade AC, Murad AM, Mello CAL, Miguel DSCG, Gomes DBD, Racy DJ, Moraes ED, Akaishi EH, Carvalho ES, Mello ES, Filho FM, Coimbra FJF, Capareli FC, Arruda FF, Vieira FMAC, Takeda FR, Cotti GCC, Pereira GLS, Paulo GA, Ribeiro HSC, Lourenco LG, Crosara M, Toneto MG, Oliveira MB, de Lourdes Oliveira M, Begnami MD, Forones NM, Yagi O, Ashton-Prolla P, Aguillar PB, Amaral PCG, Hoff PM, Araujo RLC, Filho RPDP, Gansl RC, Gil RA, Pfiffer TEF, Souza T, Jr UR, Jesus VHF, Jr WLC, Prolla G. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of gastric cancer. Ecancermedicalscience 2020;14:1126. [PMID: 33209117 DOI: 10.3332/ecancer.2020.1126] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
217 Wu XJ, Yuan P, Li ZY, Bu ZD, Zhang LH, Wu AW, Zong XL, Li SX, Shan F, Ji X. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination. Tumour Biol. 2013;34:463-469. [PMID: 23108893 DOI: 10.1007/s13277-012-0571-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
218 Shitara K, Chin K, Yoshikawa T, Katai H, Terashima M, Ito S, Hirao M, Yoshida K, Oki E, Sasako M, Emi Y, Tsujinaka T. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. Gastric Cancer. 2017;20:175-181. [PMID: 26626800 DOI: 10.1007/s10120-015-0581-1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 6.8] [Reference Citation Analysis]
219 Zhou B, He N, Hong J, Yang T, Ng DM, Gao X, Yan K, Fan X, Zheng Z, Chen P, Zheng J, Zheng Q. HIFU for the treatment of gastric cancer with liver metastases with unsuitable indications for hepatectomy and radiofrequency ablation: a prospective and propensity score-matched study. BMC Surg 2021;21:308. [PMID: 34253213 DOI: 10.1186/s12893-021-01307-y] [Reference Citation Analysis]
220 Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643-655. [PMID: 24061039 DOI: 10.1038/nrclinonc] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
221 Chang JS, Koom WS, Lee Y, Yoon HI, Lee HS. Postoperative adjuvant chemoradiotherapy in D2-dissected gastric cancer: Is radiotherapy necessary after D2-dissection? World J Gastroenterol 2014; 20(36): 12900-12907 [PMID: 25278687 DOI: 10.3748/wjg.v20.i36.12900] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
222 Won E, Shah MA, Schöder H, Strong VE, Coit DG, Brennan MF, Kelsen DP, Janjigian YY, Tang LH, Capanu M, Rizk NP, Allen PJ, Bains MS, Ilson DH. Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience. J Gastrointest Oncol 2016;7:506-14. [PMID: 27563439 DOI: 10.21037/jgo.2016.06.01] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
223 Stewart C, Chao J, Chen YJ, Lin J, Sullivan MJ, Melstrom L, Hyung WJ, Fong Y, Paz IB, Woo Y. Multimodality management of locally advanced gastric cancer-the timing and extent of surgery. Transl Gastroenterol Hepatol 2019;4:42. [PMID: 31231709 DOI: 10.21037/tgh.2019.05.02] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
224 Yuan SQ, Nie RC, Chen S, Chen XJ, Chen YM, Xu LP, Yang LF, Zhou ZW, Peng JS, Chen YB. Selective Gastric Cancer Patients with Peritoneal Seeding Benefit from Gastrectomy after Palliative Chemotherapy: A Propensity Score Matching Analysis. J Cancer 2017;8:2231-7. [PMID: 28819425 DOI: 10.7150/jca.18932] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
225 Zhu YT, Chen XZ, Chen Y, Zhou YW, Tang LS, Luo DY, Li Q, Qiu M, Wang X, Cao D, Yang Y, Shen YL, Li ZP, Bi F, Liu JY, Gou HF. Chemoradiotherapy Is Inferior to Chemotherapy Alone in Adjuvant Setting for Signet Ring Cell Containing Gastric Cancer. Front Oncol 2020;10:570268. [PMID: 33324548 DOI: 10.3389/fonc.2020.570268] [Reference Citation Analysis]
226 Qian J, Zhu W, Wang K, Ma L, Xu J, Xu T, Røe OD, Li A, Zhou J, Shu Y. JWA loss promotes cell migration and cytoskeletal rearrangement by affecting HER2 expression and identifies a high-risk subgroup of HER2-positive gastric carcinoma patients. Oncotarget 2016;7:36865-84. [PMID: 27167206 DOI: 10.18632/oncotarget.9211] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
227 Chang JS, Choi Y, Shin J, Kim KH, Keum KC, Kim HS, Koom WS, Park EC. Patterns of Care for Radiotherapy in the Neoadjuvant and Adjuvant Treatment of Gastric Cancer: A Twelve-Year Nationwide Cohort Study in Korea. Cancer Res Treat 2018;50:118-28. [PMID: 28279066 DOI: 10.4143/crt.2016.575] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
228 Schwarz RE. Current status of management of malignant disease: current management of gastric cancer. J Gastrointest Surg. 2015;19:782-788. [PMID: 25591828 DOI: 10.1007/s11605-014-2707-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
229 Kilic L, Ordu C, Yildiz I, Sen F, Keskin S, Ciftci R, Pilanci KN. Current adjuvant treatment modalities for gastric cancer: From history to the future. World J Gastrointest Oncol 2016; 8(5): 439-449 [PMID: 27190583 DOI: 10.4251/wjgo.v8.i5.439] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
230 Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8:CD004064. [PMID: 28850174 DOI: 10.1002/14651858.cd004064.pub4] [Cited by in Crossref: 77] [Cited by in F6Publishing: 162] [Article Influence: 19.3] [Reference Citation Analysis]
231 Liu WT, Liu WB, Gao M, Zhang YY, Gu KS. Expression of ALDH1A1 and CD133 is associated with the prognosis and effect of different chemotherapeutic regimens in gastric cancer. Oncol Lett 2019;18:4573-82. [PMID: 31611965 DOI: 10.3892/ol.2019.10798] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
232 Sun KK, Wang QH, Wu YY. Challenges surrounding postoperative adjuvant chemotherapy for T2N0 gastric cancer. Oncol Lett 2020;20:126. [PMID: 32934695 DOI: 10.3892/ol.2020.11985] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
233 Liu G, Zhao H, Ding Q, Li H, Liu T, Yang H, Liu Y. CDK6 is stimulated by hyperthermia and protects gastric cancer cells from hyperthermia‑induced damage. Mol Med Rep 2021;23:240. [PMID: 33537819 DOI: 10.3892/mmr.2021.11879] [Reference Citation Analysis]
234 Citterio C, Baccini M, Orlandi E, Di Nunzio C, Cavanna L. Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis. Oncotarget. 2018;9:29801-29809. [PMID: 30038721 DOI: 10.18632/oncotarget.25639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
235 Seshadri RA, Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol 2016; 22(3): 1114-1130 [PMID: 26811651 DOI: 10.3748/wjg.v22.i3.1114] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
236 Wang Q, Liu X, Chen C, Chen J, Xu B, Chen L, Zhou J, Huang Y, Chen W, Teng R, Zhao W, Jin L, Shen J, Shen J, Yen Y, Wang L. A predictive signature for oxaliplatin and 5-fluorouracil based chemotherapy in locally advanced gastric cancer. Transl Oncol 2021;14:100901. [PMID: 33091827 DOI: 10.1016/j.tranon.2020.100901] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
237 Zhou ML, Kang M, Li GC, Guo XM, Zhang Z. Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis. World J Surg Oncol 2016;14:209. [PMID: 27502921 DOI: 10.1186/s12957-016-0957-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
238 Qiu M, Peng XC, Bi F, Wang X, Li Q, Xu F, Li ZP, Shen YL, Liu JY, Zhao YQ, Cao D, Gou HF, Yang Y, Chen Y, Yi C. Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer. Med Oncol 2015;32:191. [PMID: 26025485 DOI: 10.1007/s12032-015-0635-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
239 Wang Y, He K, Zhou Z, Zhong Y, Li G, Lu J. A Retrospective Study of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. Cancer Manag Res 2020;12:8491-6. [PMID: 32982442 DOI: 10.2147/CMAR.S267330] [Reference Citation Analysis]
240 Min JS, Lee CM, Choi SI, Seo KW, Park DJ, Baik YH, Son MW, Choi WH, Kim S, Pak KH, Kim MG, Park JM, Jeong SH, Lee MS, Park S. Who Can Perform Adjuvant Chemotherapy Treatment for Gastric Cancer? A Multicenter Retrospective Overview of the Current Status in Korea. J Gastric Cancer 2018;18:264-73. [PMID: 30276003 DOI: 10.5230/jgc.2018.18.e29] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
241 Chen K, Xu XW, Mou YP, Pan Y, Zhou YC, Zhang RC, Wu D. Systematic review and meta-analysis of laparoscopic and open gastrectomy for advanced gastric cancer. World J Surg Oncol. 2013;11:182. [PMID: 23927773 DOI: 10.1186/1477-7819-11-182] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
242 Deng W, Wang QW, Zhang XT, Lu M, Li J, Li Y, Gong JF, Zhou J, Lu ZH, Shen L. Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer. World J Gastroenterol 2014; 20(12): 3356-3363 [PMID: 24696615 DOI: 10.3748/wjg.v20.i12.3356] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
243 Lee KW, Lee SS, Hwang JE, Jang HJ, Lee HS, Oh SC, Lee SH, Sohn BH, Kim SB, Shim JJ, Jeong W, Cha M, Cheong JH, Cho JY, Lim JY, Park ES, Kim SC, Kang YK, Noh SH, Ajani JA, Lee JS. Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. Clin Cancer Res 2016;22:6228-35. [PMID: 27654712 DOI: 10.1158/1078-0432.CCR-15-2468] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
244 Cartwright E, Cunningham D. The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer. Curr Treat Options Oncol 2017;18:69. [PMID: 29143893 DOI: 10.1007/s11864-017-0510-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
245 Yoon S, Yoo C, Ryu MH, Kang MJ, Ryoo BY, Park SR, Yook JH, Oh ST, Yoo MW, Kim BS. Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB-IV gastric cancer. Gastric Cancer. 2017;20:182-189. [PMID: 26661592 DOI: 10.1007/s10120-015-0580-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
246 Sexton RE, Al Hallak MN, Diab M, Azmi AS. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev 2020;39:1179-203. [PMID: 32894370 DOI: 10.1007/s10555-020-09925-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
247 Lim DH. Postoperative adjuvant radiotherapy for patients with gastric adenocarcinoma. J Gastric Cancer 2012;12:205-9. [PMID: 23346491 DOI: 10.5230/jgc.2012.12.4.205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
248 Roh CK, Choi YY, Choi S, Seo WJ, Cho M, Jang E, Son T, Kim HI, Kim H, Hyung WJ, Huh YM, Noh SH, Cheong JH. Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial. Yonsei Med J 2019;60:132-9. [PMID: 30666834 DOI: 10.3349/ymj.2019.60.2.132] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
249 Nie RC, Yuan SQ, Chen XJ, Chen S, Xu LP, Chen YM, Zhu BY, Sun XW, Zhou ZW, Chen YB. Endoscopic ultrasonography compared with multidetector computed tomography for the preoperative staging of gastric cancer: a meta-analysis. World J Surg Oncol 2017;15:113. [PMID: 28577563 DOI: 10.1186/s12957-017-1176-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
250 Liu JY, Yang GF, Chen FF, Peng CW. Evaluating the prognostic significance of tumor-infiltrating lymphocytes in solid tumor: practice of a standardized method from the International Immuno-Oncology Biomarkers Working Group. Cancer Manag Res 2019;11:6815-27. [PMID: 31440080 DOI: 10.2147/CMAR.S201538] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
251 Yura M, Takano K, Adachi K, Hara A, Hayashi K, Tajima Y, Kaneko Y, Ikoma Y, Fujisaki H, Hirata A, Hongo K, Yo K, Yoneyama K, Dehari R, Koyanagi K, Nakagawa M. Pancreaticoduodenectomy after neoadjuvant chemotherapy for gastric cancer invading the pancreatic head: A case report. World J Gastroenterol 2021; 27(6): 534-544 [PMID: 33642827 DOI: 10.3748/wjg.v27.i6.534] [Reference Citation Analysis]
252 Lim JY, Yoon SO, Hong SW, Kim JW, Choi SH, Cho JY. Thioredoxin and thioredoxin-interacting protein as prognostic markers for gastric cancer recurrence. World J Gastroenterol 2012; 18(39): 5581-5588 [PMID: 23112551 DOI: 10.3748/wjg.v18.i39.5581] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
253 Shang C, Sun L, Zhang J, Zhao B, Chen X, Xu H, Huang B. Silence of cancer susceptibility candidate 9 inhibits gastric cancer and reverses chemoresistance. Oncotarget. 2017;8:15393-15398. [PMID: 28146436 DOI: 10.18632/oncotarget.14871] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 9.5] [Reference Citation Analysis]
254 Carcas LP. Gastric cancer review. J Carcinog. 2014;13:14. [PMID: 25589897 DOI: 10.4103/1477-3163.146506] [Cited by in Crossref: 126] [Cited by in F6Publishing: 126] [Article Influence: 18.0] [Reference Citation Analysis]
255 Aoyama T, Nishikawa K, Takiguchi N, Tanabe K, Imano M, Fukushima R, Sakamoto J, Oba MS, Morita S, Kono T, Tsuburaya A. Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis. Cancer Chemother Pharmacol 2014;73:1047-54. [PMID: 24652604 DOI: 10.1007/s00280-014-2440-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
256 Xia JT, Chen LZ, Jian WH, Wang KB, Yang YZ, He WL, He YL, Chen D, Li W. MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-κB signaling. J Transl Med. 2014;12:33. [PMID: 24495516 DOI: 10.1186/1479-5876-12-33] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 9.1] [Reference Citation Analysis]
257 Choi YY, Noh SH, Cheong JH. Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine. Yonsei Med J 2015;56:1177-85. [PMID: 26256958 DOI: 10.3349/ymj.2015.56.5.1177] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
258 Chang SH, Kim SN, Choi HJ, Park M, Kim RB, Go SI, Lee WS. Adjuvant Chemotherapy for Advanced Gastric Cancer in Elderly and Non-elderly Patients: Meta-Analysis of Randomized Controlled Trials. Cancer Res Treat. 2017;49:263-273. [PMID: 27384158 DOI: 10.4143/crt.2016.054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
259 Kim H, Seo S, Kim K, Park YH, An M, Baik H, Choi C, Oh S. Prognostic significance of Human epidermal growth factor receptor-2 expression in patients with resectable gastric adenocarcinoma. World J Surg Oncol 2019;17:122. [PMID: 31296222 DOI: 10.1186/s12957-019-1652-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
260 Kocoglu H, Dogan H, Oguz B, Ocak Serin S, Okuturlar Y, Gunaldi M, Erismis B, Ozdemir B, Tural D, Hursitoglu M, Harmankaya O, Kumbasar A. Comparison of Survival Rates, Tumor Stages, and Localization in between Obese and Nonobese Patients with Gastric Cancer. Gastroenterol Res Pract 2016;2016:9382750. [PMID: 27418926 DOI: 10.1155/2016/9382750] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
261 Lee CM, Yoo MW, Son YG, Oh SJ, Kim JH, Kim HI, Park JM, Hur H, Jee YS, Hwang SH, Jin SH, Lee SE, Park JH, Seo KW, Park S, Kim CH, Jeong IH, Lee HH, Choi SI, Lee SI, Kim CY, Kim IH, Son MW, Pak KH, Kim S, Lee MS, Min JS. Long-term Efficacy of S-1 Monotherapy or Capecitabine Plus Oxaliplatin as Adjuvant Chemotherapy for Patients with Stage II or III Gastric Cancer after Curative Gastrectomy: a Propensity Score-Matched Multicenter Cohort Study. J Gastric Cancer 2020;20:152-64. [PMID: 32595999 DOI: 10.5230/jgc.2020.20.e13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
262 Shin J, Lim JS, Huh YM, Kim JH, Hyung WJ, Chung JJ, Han K, Kim S. A radiomics-based model for predicting prognosis of locally advanced gastric cancer in the preoperative setting. Sci Rep 2021;11:1879. [PMID: 33479398 DOI: 10.1038/s41598-021-81408-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
263 Jin L, Ma XM, Wang TT, Yang Y, Zhang N, Zeng N, Bai ZG, Yin J, Zhang J, Ding GQ, Zhang ZT. Psoralen Suppresses Cisplatin-Mediated Resistance and Induces Apoptosis of Gastric Adenocarcinoma by Disruption of the miR196a-HOXB7-HER2 Axis. Cancer Manag Res 2020;12:2803-27. [PMID: 32368152 DOI: 10.2147/CMAR.S248094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
264 Kashfi SM, Behboudi Farahbakhsh F, Nazemalhosseini Mojarad E, Mashayekhi K, Azimzadeh P, Romani S, Derakhshani S, Malekpour H, Asadzadeh Aghdaei H, Zali MR. Interleukin-16 polymorphisms as new promising biomarkers for risk of gastric cancer. Tumour Biol 2016;37:2119-26. [PMID: 26346169 DOI: 10.1007/s13277-015-4013-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
265 Bhat G. Retrospective study of oxaliplatin, leucovarin and 5 fluoruracil regimen in patients with advanced gastric cancer with poor performance status: A study at a tertiary center of South India. South Asian J Cancer 2018;7:223-5. [PMID: 30430088 DOI: 10.4103/sajc.sajc_1_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Yin S, Wang P, Xu X, Tan Y, Huang J, Xu H. The optimal strategy of multimodality therapies for resectable gastric cancer: evidence from a network meta-analysis. J Cancer. 2019;10:3094-3101. [PMID: 31289579 DOI: 10.7150/jca.30456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
267 Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S, Wang J, Xu N, Cheng Y, Bai Y. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. BMC Cancer. 2016;16:68. [PMID: 26857702 DOI: 10.1186/s12885-016-2092-9] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 8.6] [Reference Citation Analysis]
268 Li G, Zhang Z, Ma X, Zhu J, Cai G. Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction. PLoS One 2013;8:e54233. [PMID: 23372688 DOI: 10.1371/journal.pone.0054233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
269 Li G, Wang G, Chi F, Jia Y, Wang X, Mu Q, Qin K, Zhu X, Pang J, Xu B, Feng G, Niu Y, Gong T, Zhang H, Dong X, Liu T, Ma J, Gao Z, Tao K, Li F, Xu J, Yu B. Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer. J Immunother Cancer 2021;9:e002218. [PMID: 33753568 DOI: 10.1136/jitc-2020-002218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
270 Zurlo IV, Basso M, Strippoli A, Calegari MA, Orlandi A, Cassano A, Di Salvatore M, Garufi G, Bria E, Tortora G, Barone C, Pozzo C. Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren's Classification in Pan-Cancer Analysis Era? Cancers (Basel) 2020;12:E1749. [PMID: 32630186 DOI: 10.3390/cancers12071749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
271 Chen Y, Liu D, Xiao J, Xiang J, Liu A, Chen S, Liu J, Hu X, Peng J. Nomogram for Predicting Survival in Advanced Gastric Cancer after Neoadjuvant Chemotherapy and Radical Surgery. Gastroenterol Res Pract 2021;2021:2923700. [PMID: 34367276 DOI: 10.1155/2021/2923700] [Reference Citation Analysis]
272 Lee CK, Jung M, Kim HS, Jung I, Shin DB, Kang SY, Zang DY, Kim KH, Lee MH, Kim BS, Lee KH, Cheong JH, Hyung WJ, Noh SH, Chung HC, Rha SY. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. Cancer Res Treat 2019;51:1-11. [PMID: 29397659 DOI: 10.4143/crt.2018.028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
273 Samalin E, Ychou M. Neoadjuvant therapy for gastroesophageal adenocarcinoma. World J Clin Oncol 2016; 7(3): 284-292 [PMID: 27298768 DOI: 10.5306/wjco.v7.i3.284] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
274 Kitano T, Aisu Y, Yasukawa D, Hori T. Aggressive Graphic/Surgical R0 Resection and Jejunal Interposition with Preservation of Mesojejunal Autonomic Nerves in Patients with Stage IV Esophagogastric Junction Adenocarcinoma: A Report of 3 Cases. Am J Case Rep. 2019;20:465-473. [PMID: 30952831 DOI: 10.12659/ajcr.913960] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
275 Pereira MA, Ramos MFKP, Dias AR, Faraj SF, Cirqueira CDS, de Mello ES, Zilberstein B, Alves VAF, Ribeiro U Jr. Immunohistochemical expression of thymidylate synthase and prognosis in gastric cancer patients submitted to fluoropyrimidine-based chemotherapy. Chin J Cancer Res 2018;30:526-36. [PMID: 30510364 DOI: 10.21147/j.issn.1000-9604.2018.05.06] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
276 Galizia G, Lieto E, Auricchio A, Cardella F, Mabilia A, Diana A, Castellano P, De Vita F, Orditura M. Comparison of the current AJCC-TNM numeric-based with a new anatomical location-based lymph node staging system for gastric cancer: A western experience. PLoS One 2017;12:e0173619. [PMID: 28380037 DOI: 10.1371/journal.pone.0173619] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
277 Chen K, Xu X, Mou Y, Pan Y, Zhang R, Zhou Y, Wu D, Huang C. Totally laparoscopic distal gastrectomy with D2 lymphadenectomy and Billroth II gastrojejunostomy for gastric cancer: short- and medium-term results of 139 consecutive cases from a single institution. Int J Med Sci. 2013;10:1462-1470. [PMID: 24046519 DOI: 10.7150/ijms.6632] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
278 Lordick F, Lorenzen S, Yamada Y, Ilson D. Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer. 2014;17:213-225. [PMID: 24048758 DOI: 10.1007/s10120-013-0297-z] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 8.8] [Reference Citation Analysis]
279 Fujitani K, Tamura S, Kimura Y, Matsuyama J, Imamura H, Yamamoto K, Fujita J, Iijima S, Ueda S, Kurokawa Y, Shimokawa T, Satoh T; Osaka Gastrointestinal Cancer Chemotherapy Study Group. Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002). Gastric Cancer. 2020;23:520-530. [PMID: 31667688 DOI: 10.1007/s10120-019-01023-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
280 Mori M, Shuto K, Kosugi C, Narushima K, Hayashi H, Matsubara H, Koda K. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer. BMC Cancer 2018;18:1261. [PMID: 30558575 DOI: 10.1186/s12885-018-5171-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
281 Song BI, Kim HW, Won KS, Ryu SW, Sohn SS, Kang YN. Preoperative Standardized Uptake Value of Metastatic Lymph Nodes Measured by 18F-FDG PET/CT Improves the Prediction of Prognosis in Gastric Cancer. Medicine (Baltimore). 2015;94:e1037. [PMID: 26131811 DOI: 10.1097/md.0000000000001037] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
282 Chen L, Shi Y, Yuan J, Wu Q, Han Y, Qin R, Jia B, Wei B, Wei L, Dai G, Jiao S. Evaluation of docetaxel- and oxaliplatin-based adjuvant chemotherapy in postgastrectomy gastric cancer patients reveals obvious survival benefits in docetaxel-treated mixed signet ring cell carcinoma patients. Med Oncol. 2014;31:159. [PMID: 25119501 DOI: 10.1007/s12032-014-0159-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
283 Yuan SQ, Wu WJ, Qiu MZ, Wang ZX, Yang LP, Jin Y, Yun JP, Gao YH, Li YH, Zhou ZW, Wang F, Xu RH. Development and Validation of a Nomogram to Predict the Benefit of Adjuvant Radiotherapy for Patients with Resected Gastric Cancer. J Cancer 2017;8:3498-505. [PMID: 29151934 DOI: 10.7150/jca.19879] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
284 Eom BW, Kim S, Kim JY, Yoon HM, Kim MJ, Nam BH, Kim YW, Park YI, Park SR, Ryu KW. Survival Benefit of Perioperative Chemotherapy in Patients with Locally Advanced Gastric Cancer: a Propensity Score Matched Analysis. J Gastric Cancer. 2018;18:69-81. [PMID: 29629222 DOI: 10.5230/jgc.2018.18.e9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
285 Zhao B, Blair SL, Katz MHG, Lowy AM, Kelly KJ. Adherence with operative standards in the treatment of gastric cancer in the United States. Gastric Cancer 2020;23:550-60. [PMID: 31745679 DOI: 10.1007/s10120-019-01028-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
286 Kim ST, Oh SY, Lee J, Kang JH, Lee HW, Lee MA, Sohn BS, Hong JH, Park YS, Park JO, Lim HY. Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial. J Cancer 2019;10:6185-90. [PMID: 31772650 DOI: 10.7150/jca.37610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
287 Eun H, Hur H, Byun CS, Son SY, Han SU, Cho YK. Effects of Continuing Adjuvant S-1 for 1 Year on the Prognosis of Gastric Cancer Patients: Results from a Prospective Single Center Study. J Gastric Cancer 2015;15:113-20. [PMID: 26161284 DOI: 10.5230/jgc.2015.15.2.113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
288 Slagter AE, Vollebergh MA, Jansen EPM, van Sandick JW, Cats A, van Grieken NCT, Verheij M. Towards Personalization in the Curative Treatment of Gastric Cancer. Front Oncol. 2020;10:614907. [PMID: 33330111 DOI: 10.3389/fonc.2020.614907] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
289 Choi AH, Kim J, Chao J. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. World J Gastroenterol 2015; 21(24): 7343-7348 [PMID: 26139980 DOI: 10.3748/wjg.v21.i24.7343] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 39] [Article Influence: 7.7] [Reference Citation Analysis]
290 Inoue H, Kosuga T, Kubota T, Konishi H, Shiozaki A, Okamoto K, Fujiwara H, Otsuji E. Significance of a preoperative systemic immune-inflammation index as a predictor of postoperative survival outcomes in gastric cancer. World J Surg Oncol 2021;19:173. [PMID: 34118953 DOI: 10.1186/s12957-021-02286-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
291 Elimova E, Slack RS, Chen HC, Planjery V, Shiozaki H, Shimodaira Y, Charalampakis N, Lin Q, Harada K, Wadhwa R, Estrella JS, Kaya DM, Sagebiel T, Lee JH, Weston B, Bhutani M, Murphy MB, Matamoros A, Minsky B, Das P, Mansfield PF, Badgwell BD, Ajani JA. Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. Oncotarget 2017;8:81430-40. [PMID: 29113402 DOI: 10.18632/oncotarget.19226] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
292 Sirohi B, Ostwal V, Dawood S, Lopes G, Talole S, Nashikkar C, Shrikhande S. Oxaliplatin-related neuropathy in Indian patients - no difference between generic and original molecules. Indian J Med Paediatr Oncol 2016;37:271-7. [PMID: 28144095 DOI: 10.4103/0971-5851.195745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
293 Yu S, Wang Y, Cheng X, Lv M, Cui Y, Li W, Yu Y, Li Q, Liu T. Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients. Cancer Manag Res 2020;12:10091-101. [PMID: 33116865 DOI: 10.2147/CMAR.S270387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
294 Wang C, Xi W, Jiang J, Ji J, Yu Y, Zhu Z, Zhang J. Metronomic chemotherapy remodel cancer-associated fibroblasts to decrease chemoresistance of gastric cancer in nude mice. Oncol Lett 2017;14:7903-9. [PMID: 29344235 DOI: 10.3892/ol.2017.7197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
295 Xie R, Liu J, Yu X, Li C, Wang Y, Yang W, Hu J, Liu P, Sui H, Liang P, Huang X, Wang L, Bai Y, Xue Y, Zhu J, Fang T. ANXA2 Silencing Inhibits Proliferation, Invasion, and Migration in Gastric Cancer Cells. J Oncol. 2019;2019. [PMID: 31186633 DOI: 10.1155/2019/4035460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
296 Lazăr DC, Tăban S, Cornianu M, Faur A, Goldiş A. New advances in targeted gastric cancer treatment. World J Gastroenterol 2016; 22(30): 6776-6799 [PMID: 27570417 DOI: 10.3748/wjg.v22.i30.6776] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 46] [Article Influence: 9.6] [Reference Citation Analysis]
297 Zhu BY, Yuan SQ, Nie RC, Li SM, Yang LR, Duan JL, Chen YB, Zhang XS. Prognostic Factors and Recurrence Patterns in T4 Gastric Cancer Patients after Curative Resection. J Cancer 2019;10:1181-8. [PMID: 30854127 DOI: 10.7150/jca.28993] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
298 Che K, Liu F, Wu N, Liu Q, Yuan L, Wei J. Individualized prediction of survival benefits from perioperative chemoradiotherapy for patients with resectable gastric cancer. Cancer Med 2020;9:7137-50. [PMID: 32810384 DOI: 10.1002/cam4.3350] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
299 Song KY, Park YG, Jeon HM, Park CH. A nomogram for predicting individual survival of patients with gastric cancer who underwent radical surgery with extended lymph node dissection. Gastric Cancer 2014;17:287-93. [PMID: 23712439 DOI: 10.1007/s10120-013-0270-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
300 Matsumoto R, Mori S, Kita Y, Toda H, Sasaki K, Arigami T, Matsushita D, Kurahara H, Maemura K, Natsugoe S. Multiple liver metastases with synchronous gastric and transverse colon cancer diagnosed by gastric perforation successfully treated by SOX plus bevacizumab and completely resected by surgery: a case report. Surg Case Rep 2020;6:51. [PMID: 32180030 DOI: 10.1186/s40792-020-00808-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
301 Yu Y, Fang Y, Shen Z, Wang Y, Yan M, Cao H, Liu Y, Wang X, Cui Y, Liu F, Chen W, Li W, Li Q, Jiang H, Sun Y, Liu T. Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO-CLASSIC Study. Oncologist. 2019;. [PMID: 31239311 DOI: 10.1634/theoncologist.2019-0416] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
302 Wu B, Li T, Cai J, Xu Y, Zhao G. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer 2014;14:984. [PMID: 25526802 DOI: 10.1186/1471-2407-14-984] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
303 Kim YW, Kim MJ, Ryu KW, Lim HS, Lee JH, Kong SY, Lee JS, Choi IJ, Kim CG, Lee JY, Cho SJ, Kook MC, Park YI, Kim SK, Park SR. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival. Gastric Cancer 2016;19:586-96. [PMID: 25851942 DOI: 10.1007/s10120-015-0490-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
304 Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, Nagao N, Takahashi M, Takagane A, Watanabe T, Kaji M, Okitsu H, Nomura T, Matsui T, Yoshikawa T, Matsuyama J, Yamada M, Ito S, Takeuchi M, Fujii M. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. J Clin Oncol. 2019;37:1296-1304. [PMID: 30925125 DOI: 10.1200/jco.18.01138] [Cited by in Crossref: 80] [Cited by in F6Publishing: 42] [Article Influence: 40.0] [Reference Citation Analysis]
305 Kang KK, Hur H, Byun CS, Kim YB, Han SU, Cho YK. Conventional cytology is not beneficial for predicting peritoneal recurrence after curative surgery for gastric cancer: results of a prospective clinical study. J Gastric Cancer. 2014;14:23-31. [PMID: 24765534 DOI: 10.5230/jgc.2014.14.1.23] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
306 Ahn GT, Baek SK, Han JJ, Kim HJ, Jeong SJ, Maeng CH. Optimal time interval from surgery to adjuvant chemotherapy in gastric cancer. Oncol Lett 2020;20:32. [PMID: 32774505 DOI: 10.3892/ol.2020.11893] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
307 Zheng ZF, Lu J, Xie JW, Wang JB, Lin JX, Chen QY, Cao LL, Lin M, Tu RH, Zheng CH, Huang CM, Li P. Preoperative skeletal muscle index vs the controlling nutritional status score: Which is a better objective predictor of long-term survival for gastric cancer patients after radical gastrectomy? Cancer Med 2018;7:3537-47. [PMID: 29953752 DOI: 10.1002/cam4.1548] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
308 Elimova E, Shiozaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, Blum MA, Badgwell B, Das P, Song S, Ajani JA. Medical management of gastric cancer: A 2014 update. World J Gastroenterol 2014; 20(38): 13637-13647 [PMID: 25320502 DOI: 10.3748/wjg.v20.i38.13637] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
309 Zaidi A, Khan A, Duval C, Haider K, Ahmed O, Dueck DA, Brunet B, Gardiner D, Ahmed S. Comparison of Perioperative Chemotherapy versus Postoperative Chemoradiotherapy for Operable Stomach Cancer: A Western Canadian Province Experience. Curr Oncol 2021;28:1262-73. [PMID: 33802661 DOI: 10.3390/curroncol28020120] [Reference Citation Analysis]
310 Batista TP, de Mendonça LM, Fassizoli-Fonte AL. The role of perioperative radiotherapy in gastric cancer. Oncol Rev 2012;6:e23. [PMID: 25992221 DOI: 10.4081/oncol.2012.e23] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
311 de Jesus VHF, da Costa WL Jr, Felismino TC, Calsavara VF, Diniz AL, de Castro Ribeiro HS, de Godoy AL, de Farias IC, Coimbra FJF. Survival outcomes of patients with pathological stage I gastric cancer using the competing risks survival method. J Gastrointest Oncol 2019;10:1110-9. [PMID: 31949928 DOI: 10.21037/jgo.2019.10.04] [Reference Citation Analysis]
312 Quadri HS, Smaglo BG, Morales SJ, Phillips AC, Martin AD, Chalhoub WM, Haddad NG, Unger KR, Levy AD, Al-Refaie WB. Gastric Adenocarcinoma: A Multimodal Approach.Front Surg. 2017;4:42. [PMID: 28824918 DOI: 10.3389/fsurg.2017.00042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
313 Alsina M, Miquel JM, Diez M, Castro S, Tabernero J. How I treat gastric adenocarcinoma. ESMO Open. 2019;4:e000521. [PMID: 31354966 DOI: 10.1136/esmoopen-2019-000521] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
314 Foo M, Leong T. Adjuvant therapy for gastric cancer: Current and future directions. World J Gastroenterol 2014; 20(38): 13718-13727 [PMID: 25320509 DOI: 10.3748/wjg.v20.i38.13718] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
315 Shum H, Rajdev L. Multimodality management of resectable gastric cancer: A review. World J Gastrointest Oncol 2014; 6(10): 393-402 [PMID: 25320655 DOI: 10.4251/wjgo.v6.i10.393] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
316 Zhang S, Zang D, Cheng Y, Li Z, Yang B, Guo T, Liu Y, Qu X, Che X. Identification of Key Gene and Pathways for the Prediction of Peritoneal Metastasis of Gastric Cancer by Co-expression Analysis. J Cancer 2020;11:3041-51. [PMID: 32226519 DOI: 10.7150/jca.39645] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
317 Kanda M, Tanaka H, Shimizu D, Miwa T, Umeda S, Tanaka C, Kobayashi D, Hattori N, Suenaga M, Hayashi M, Iwata N, Yamada S, Fujiwara M, Kodera Y. SYT7 acts as a driver of hepatic metastasis formation of gastric cancer cells. Oncogene. 2018;37:5355-5366. [PMID: 29858600 DOI: 10.1038/s41388-018-0335-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
318 Slagter AE, Jansen EPM, van Laarhoven HWM, van Sandick JW, van Grieken NCT, Sikorska K, Cats A, Muller-Timmermans P, Hulshof MCCM, Boot H, Los M, Beerepoot LV, Peters FPJ, Hospers GAP, van Etten B, Hartgrink HH, van Berge Henegouwen MI, Nieuwenhuijzen GAP, van Hillegersberg R, van der Peet DL, Grabsch HI, Verheij M. CRITICS-II: A multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer. 2018;18:877. [PMID: 30200910 DOI: 10.1186/s12885-018-4770-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 15.7] [Reference Citation Analysis]
319 Kim IH. Current status of adjuvant chemotherapy for gastric cancer. World J Gastrointest Oncol 2019; 11(9): 679-685 [PMID: 31558973 DOI: 10.4251/wjgo.v11.i9.679] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
320 Xu AM, Huang L, Liu W, Gao S, Han WX, Wei ZJ. Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9:e86941. [PMID: 24497999 DOI: 10.1371/journal.pone.0086941.ecollection] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
321 Sah BK, Xu W, Zhang B, Zhang H, Yuan F, Li J, Liu W, Yan C, Li C, Yan M, Zhu Z. Feasibility and Safety of Perioperative Chemotherapy With Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel for Locally Advanced Gastric Cancer Patients in China. Front Oncol 2020;10:567529. [PMID: 33537232 DOI: 10.3389/fonc.2020.567529] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
322 Lordick F, Hoffmeister A. [Treatment of gastric cancer]. Internist (Berl) 2014;55:15-6, 18-22. [PMID: 24154498 DOI: 10.1007/s00108-013-3317-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
323 Wang W, Xiong W, Liu Z, Luo L, Zheng Y, Tan P, Diao D, Zou L, Wan J. Clinical significance of No. 10 and 11 lymph nodes posterior to the splenic vessel in D2 radical total gastrectomy: An observational study. Medicine (Baltimore) 2016;95:e4581. [PMID: 27512888 DOI: 10.1097/MD.0000000000004581] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
324 Jeong JH, Park SR, Ahn Y, Ryu MH, Ryoo BY, Kong SY, Yook JH, Yoo MW, Kim BS, Kim BS, Kang YK. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer. Gastric Cancer 2017;20:146-55. [PMID: 26715117 DOI: 10.1007/s10120-015-0586-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
325 Lee HY, Hwang IG, Park SE, Kim MJ, Park SH, Kang JH, Kim YS, Oh SY, Won YW, Lee SI, Ji JH, Chi KC. Factors Influencing Clinicians' Choice of Adjuvant S-1 versus Capecitabine plus Oxaliplatin after Curative Gastrectomy in Patients with Gastric Cancer. J Cancer 2016;7:1711-5. [PMID: 27698908 DOI: 10.7150/jca.15598] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
326 Zhou N, Qu Y, Xu C, Tang Y. Upregulation of microRNA-375 increases the cisplatin-sensitivity of human gastric cancer cells by regulating ERBB2. Exp Ther Med. 2016;11:625-630. [PMID: 26893657 DOI: 10.3892/etm.2015.2920] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
327 Giampieri R, Del Prete M, Cantini L, Baleani MG, Bittoni A, Maccaroni E, Berardi R. Optimal management of resected gastric cancer. Cancer Manag Res 2018;10:1605-18. [PMID: 29950898 DOI: 10.2147/CMAR.S151552] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
328 Farrow NE, Freischlag KW, Adam MA, Blazer DG. Impact of minimally invasive gastrectomy on use of and time to adjuvant chemotherapy for gastric adenocarcinoma. J Surg Oncol 2020;121:486-93. [PMID: 31919862 DOI: 10.1002/jso.25834] [Reference Citation Analysis]
329 Aoyama T, Yoshikawa T. Adjuvant therapy for locally advanced gastric cancer. Surg Today. 2017;47:1295-1302. [PMID: 28251375 DOI: 10.1007/s00595-017-1493-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
330 Tan YE, Wang PL, Yin SC, Zhang C, Hou WB, Xu HM. Thirty-year trends in clinicopathologic characteristics and prognosis after gastrectomy for gastric cancer: A single institution in Northern China. J Cancer 2020;11:1056-62. [PMID: 31956352 DOI: 10.7150/jca.36927] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
331 Oshima T, Yoshikawa T, Miyagi Y, Morita S, Yamamoto M, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, Yokose T, Hiroshima Y, Aoyama T, Hayashi T, Ogata T, Cho H, Rino Y, Masuda M, Tsuburaya A, Sakamoto J. Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial. Oncotarget 2020;11:2906-18. [PMID: 32774771 DOI: 10.18632/oncotarget.27658] [Reference Citation Analysis]
332 Palugulla S, Dkhar SA, Kayal S, Narayan SK. Oxaliplatin-induced Peripheral Neuropathy in South Indian Cancer Patients: A Prospective Study in Digestive Tract Cancer Patients. Indian J Med Paediatr Oncol 2017;38:502-7. [PMID: 29333020 DOI: 10.4103/ijmpo.ijmpo_143_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
333 Ito S, Ohashi Y, Sasako M. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial. BMC Cancer 2018;18:449. [PMID: 29678146 DOI: 10.1186/s12885-018-4341-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
334 Zhu X, Ko YJ, Berry S, Shah K, Lee E, Chan K. A Bayesian network meta-analysis on second-line systemic therapy in advanced gastric cancer. Gastric Cancer 2017;20:646-54. [PMID: 27722826 DOI: 10.1007/s10120-016-0656-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
335 Chuang J, Gong J, Klempner SJ, Woo Y, Chao J. Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. J Gastrointest Oncol 2018;9:560-72. [PMID: 29998022 DOI: 10.21037/jgo.2018.03.01] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
336 Lin JX, Wang ZK, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Zheng CH, Huang CM, Li P. Clinicopathological features and impact of adjuvant chemotherapy on the long-term survival of patients with multiple gastric cancers: a propensity score matching analysis. Cancer Commun (Lond) 2019;39:4. [PMID: 30744696 DOI: 10.1186/s40880-019-0350-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
337 Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, Ye XS, Do IG, Liu S, Gong L, Fu J, Jin JG, Choi MG, Sohn TS, Lee JH, Bae JM, Kim ST, Park SH, Sohn I, Jung SH, Tan P, Chen R, Hardwick J, Kang WK, Ayers M, Hongyue D, Reinhard C, Loboda A, Kim S, Aggarwal A. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449-456. [PMID: 25894828 DOI: 10.1038/nm.3850] [Cited by in Crossref: 806] [Cited by in F6Publishing: 761] [Article Influence: 134.3] [Reference Citation Analysis]
338 Wang Y, Lei X, Liu Z, Shan F, Ying X, Li Z, Ji J. Short-term outcomes of laparoscopic versus open total gastrectomy after neoadjuvant chemotherapy: a cohort study using the propensity score matching method. J Gastrointest Oncol 2021;12:237-48. [PMID: 34012622 DOI: 10.21037/jgo-20-374] [Reference Citation Analysis]
339 Seo SH, Kim KH, Oh SH, Choi Y, Ahn KJ, Lee JY, Lee SM, Park J, Kim WG. Ki-67 labeling index as a prognostic marker in advanced stomach cancer. Ann Surg Treat Res 2019;96:27-33. [PMID: 30603631 DOI: 10.4174/astr.2019.96.1.27] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
340 Takahari D, Hamaguchi T, Yoshimura K, Katai H, Ito S, Fuse N, Konishi M, Yasui H, Terashima M, Goto M. Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer. Gastric Cancer. 2013;Epub ahead of print. [PMID: 23719867 DOI: 10.1007/s10120-013-0264-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
341 Smyth E, Khan K, Valeri N. Translational research and application of basic biology to clinical trial development in GI cancers. Ann Transl Med 2018;6:164. [PMID: 29911112 DOI: 10.21037/atm.2018.05.05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
342 Wang SC, Chou JF, Strong VE, Brennan MF, Capanu M, Coit DG. Pretreatment Neutrophil to Lymphocyte Ratio Independently Predicts Disease-specific Survival in Resectable Gastroesophageal Junction and Gastric Adenocarcinoma. Ann Surg. 2016;263:292-297. [PMID: 25915915 DOI: 10.1097/sla.0000000000001189] [Cited by in Crossref: 81] [Cited by in F6Publishing: 60] [Article Influence: 16.2] [Reference Citation Analysis]
343 Ma LX, Espin-Garcia O, Lim CH, Jiang DM, Sim HW, Natori A, Chan BA, Suzuki C, Chen EX, Liu G, Brar SS, Swallow CJ, Yeung JC, Darling GE, Wong RK, Kalimuthu SN, Conner J, Elimova E, Jang RW. Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastric and esophageal cancers. J Gastrointest Oncol 2020;11:356-65. [PMID: 32399276 DOI: 10.21037/jgo.2020.03.03] [Reference Citation Analysis]
344 Seshadri RA, Glehen O. The Role of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer. Indian J Surg Oncol 2016;7:198-207. [PMID: 27065710 DOI: 10.1007/s13193-016-0502-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
345 Kurimoto K, Ishigure K, Mochizuki Y, Ishiyama A, Matsui T, Ito S, Nakayama H, Tanaka N, Kobayashi D, Sakamoto J, Nakao A, Kodera Y. A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for stage III/IV gastric cancer (CCOG 1106). Gastric Cancer 2015;18:354-9. [PMID: 24838732 DOI: 10.1007/s10120-014-0384-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
346 Choi YY, Cho M, Kwon IG, Son T, Kim HI, Choi SH, Cheong JH, Hyung WJ. Ten Thousand Consecutive Gastrectomies for Gastric Cancer: Perspectives of a Master Surgeon. Yonsei Med J 2019;60:235-42. [PMID: 30799586 DOI: 10.3349/ymj.2019.60.3.235] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
347 Lin JX, Lin JP, Li P, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Zheng CH, Huang CM. New metastatic lymph node classification for early gastric cancer should differ from those for advanced gastric adenocarcinoma: Results based on the SEER database. World J Clin Cases 2019; 7(2): 145-155 [PMID: 30705892 DOI: 10.12998/wjcc.v7.i2.145] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
348 Chan MM, Sjoquist KM, Zalcberg JR. Clinical utility of ramucirumab in advanced gastric cancer. Biologics 2015;9:93-105. [PMID: 26451083 DOI: 10.2147/BTT.S62777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
349 Chongqing T, Liubao P, Xiaohui Z, Jianhe L, Xiaomin W, Gannong C, Siying W, Lihui O, Ziying Z. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer. Pharmacoeconomics 2014;32:235-43. [PMID: 23709451 DOI: 10.1007/s40273-013-0065-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
350 Hwang JE, Ki MS, Kim K, Jung SH, Shim HJ, Bae WK, Hwang EC, Hur YH, Jeong O, Ryu SY, Park YK, Cho SH, Lee JS, Chung IJ. The optimal chemotherapeutic regimen in D2-resected locally advanced gastric cancer: a propensity score-matched analysis. Oncotarget 2017;8:66559-68. [PMID: 29029536 DOI: 10.18632/oncotarget.16301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
351 Gu Y, Chen Y, Jin K, Cao Y, Liu X, Lv K, He X, Lin C, Liu H, Li H, He H, Qin J, Li R, Zhang H, Zhang W. Intratumoral CD103+CD4+ T cell infiltration defines immunoevasive contexture and poor clinical outcomes in gastric cancer patients. Oncoimmunology 2020;9:1844402. [PMID: 33312758 DOI: 10.1080/2162402X.2020.1844402] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
352 Yoshii T, Hara H, Asayama M, Kumekawa Y, Miyazawa S, Takahashi N, Matsushima T, Shimizu S, Saito Y. Chemoradiotherapy with FOLFOX for esophageal squamous cell cancer with synchronous rectal cancer: Four case reports and a literature review. Mol Clin Oncol 2020;12:23-30. [PMID: 31814973 DOI: 10.3892/mco.2019.1945] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
353 Tokunaga M, Kaito A, Sugita S, Watanabe M, Sunagawa H, Kinoshita T. Robotic gastrectomy for gastric cancer. Transl Gastroenterol Hepatol. 2017;2:57. [PMID: 28616612 DOI: 10.21037/tgh.2017.05.09] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
354 Coccolini F, Montori G, Ceresoli M, Cima S, Valli MC, Nita GE, Heyer A, Catena F, Ansaloni L. Advanced gastric cancer: What we know and what we still have to learn. World J Gastroenterol 2016; 22(3): 1139-1159 [PMID: 26811653 DOI: 10.3748/wjg.v22.i3.1139] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
355 Wang X, Li S, Sun Y, Li K, Shen X, Xue Y, Liang P, Li G, Chen L, Zhao Q, Li G, Fu W, Liang H, Xin H, Suo J, Fang X, Zheng Z, Xu Z, Chen H, Zhou Y, He Y, Huang H, Zhu L, Yang K, Ji J, Ye Y, Zhang Z, Li F, Wang X, Tian Y, Park S, Chen L. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial. BMC Cancer 2021;21:20. [PMID: 33402102 DOI: 10.1186/s12885-020-07764-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
356 Yu Y, Zhang Z, Meng Q, Ma Y, Fan X, Sun J, Wang G. Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection. Front Oncol 2021;11:684627. [PMID: 34109131 DOI: 10.3389/fonc.2021.684627] [Reference Citation Analysis]
357 Lam CG, Furman WL, Wang C, Spunt SL, Wu J, Ivy P, Santana VM, McGregor LM. Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors. J Pediatr Hematol Oncol 2015;37:e13-8. [PMID: 24942022 DOI: 10.1097/MPH.0000000000000186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
358 Shrikhande SV, Sirohi B, Barreto SG, Chacko RT, Parikh PM, Pautu J, Arya S, Patil P, Chilukuri SC, Ganesh B, Kaur T, Shukla D, Rath GS. Indian Council of Medical Research consensus document for the management of gastric cancer. Indian J Med Paediatr Oncol 2014;35:239-43. [PMID: 25538398 DOI: 10.4103/0971-5851.144970] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
359 肖鹏, 栗敏, 梅家转, 白桦. SOX方案与XELOX方案同步放疗治疗术后复发胃癌的疗效. 世界华人消化杂志 2014; 22(12): 1720-1724 [DOI: 10.11569/wcjd.v22.i12.1720] [Reference Citation Analysis]
360 Sasaki K, Onodera S, Otsuka K, Satomura H, Kurayama E, Kubo T, Takahashi M, Ito J, Nakajima M, Yamaguchi S, Miyachi K, Kato H. Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer. Med Oncol 2017;34:139. [PMID: 28707042 DOI: 10.1007/s12032-017-0997-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
361 Miwa T, Kanda M, Shimizu D, Umeda S, Sawaki K, Tanaka H, Tanaka C, Hattori N, Hayashi M, Yamada S, Nakayama G, Koike M, Kodera Y. Hepatic metastasis of gastric cancer is associated with enhanced expression of ethanolamine kinase 2 via the p53-Bcl-2 intrinsic apoptosis pathway. Br J Cancer 2021;124:1449-60. [PMID: 33531692 DOI: 10.1038/s41416-021-01271-7] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
362 Li N, Deng W, Ma J, Wei B, Guo K, Shen W, Zhang Y, Luo S. Prognostic evaluation of Nanog, Oct4, Sox2, PCNA, Ki67 and E-cadherin expression in gastric cancer. Med Oncol. 2015;32:433. [PMID: 25491144 DOI: 10.1007/s12032-014-0433-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 56] [Article Influence: 6.9] [Reference Citation Analysis]
363 Seyfried F, von Rahden BH, Miras AD, Gasser M, Maeder U, Kunzmann V, Germer CT, Pelz J, Kerscher AG. Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin--a longitudinal experience from a prospectively collected database of 1108 patients. BMC Cancer 2015;15:73. [PMID: 25879885 DOI: 10.1186/s12885-015-1081-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
364 Lee JH, Kim MG, Jung MS, Kwon SJ. Prognostic significance of lymphovascular invasion in node-negative gastric cancer. World J Surg. 2015;39:732-739. [PMID: 25376868 DOI: 10.1007/s00268-014-2846-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 4.2] [Reference Citation Analysis]
365 Gotfrit J, Goodwin R, Asmis T, Hyde AJ, Alcindor T, Aubin F, Berry S, Bossé D, Brown C, Burkes R, Burnell M, Colwell B, Corbett J, Craswell J, Daaboul N, Doherty M, Fleming DAB, Galvis L, Goel R, Harb M, Jeyakumar A, Jonker D, Kennedy E, Lock M, Mahmud A, McCrea PH, Nair V, Nassabein R, Nessim C, Ramjeesingh R, Raza M, Saliba W, Samimi S, Singh S, Snow S, Tehfé M, Thirlwell M, Valdes M, Welch S, Vickers M. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019. Curr Oncol 2021;28:1988-2006. [PMID: 34073199 DOI: 10.3390/curroncol28030185] [Reference Citation Analysis]
366 Sehdev A, Catenacci DV. Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. J Hematol Oncol 2013;6:66. [PMID: 24010946 DOI: 10.1186/1756-8722-6-66] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
367 Kim JY, Shin E, Kim JW, Lee HS, Lee DW, Kim SH, Lee JO, Kim YJ, Kim JH, Bang SM, Ahn SH, Park DJ, Lee JS, Lee JS, Kim HH, Lee KW. Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer. PLoS One 2015;10:e0120324. [PMID: 25793299 DOI: 10.1371/journal.pone.0120324] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
368 Shen J, Cao B, Wang Y, Xiao A, Qin J, Wu J, Yan Q, Hu Y, Yang C, Cao Z, Hu J, Yin P, Xie D, Gong J. Prospective randomized controlled trial to compare laparoscopic distal gastrectomy (D2 lymphadenectomy plus complete mesogastrium excision, D2 + CME) with conventional D2 lymphadenectomy for locally advanced gastric adenocarcinoma: study protocol for a randomized controlled trial. Trials 2018;19:432. [PMID: 30092843 DOI: 10.1186/s13063-018-2790-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
369 Wang T, Chen Y, Zhao L, Zhou H, Wu C, Zhang X, Zhou A, Jin J, Zhao D. The Effect of Neoadjuvant Therapies for Patients with Locally Advanced Gastric Cancer: A Propensity Score Matching Study. J Cancer 2021;12:379-86. [PMID: 33391434 DOI: 10.7150/jca.46847] [Reference Citation Analysis]
370 Kosuga T, Ichikawa D, Otsuji E. Pathologic tumor response to neoadjuvant chemotherapy in gastroesophageal cancer: what does it mean? Transl Gastroenterol Hepatol 2016;1:75. [PMID: 28138641 DOI: 10.21037/tgh.2016.09.08] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
371 Qu JL, Qu XJ, Li Z, Zhang JD, Liu J, Teng YE, Jin B, Zhao MF, Yu P, Shi J, Fu LY, Wang ZN, Liu YP. Prognostic model based on systemic inflammatory response and clinicopathological factors to predict outcome of patients with node-negative gastric cancer.PLoS One. 2015;10:e0128540. [PMID: 26075713 DOI: 10.1371/journal.pone.0128540] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
372 Honma Y, Yamada Y, Terazawa T, Takashima A, Iwasa S, Kato K, Hamaguchi T, Shimada Y, Ohashi M, Morita S, Fukagawa T, Machida N, Katai H. Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinoma. Surg Today 2016;46:1076-82. [PMID: 26563224 DOI: 10.1007/s00595-015-1276-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
373 Lv M, Zhang S, Dong Y, Cao L, Guo S. PolG Inhibits Gastric Cancer Glycolysis and Viability by Suppressing PKM2 Phosphorylation. Cancer Manag Res 2021;13:1559-70. [PMID: 33623435 DOI: 10.2147/CMAR.S292306] [Reference Citation Analysis]
374 Wang K, Li E, Busuttil RA, Kong JC, Pattison S, Sung JJY, Yu J, El-Omar EM, Simpson JA, Boussioutas A. A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer. Ther Adv Med Oncol 2020;12:1758835920930359. [PMID: 32754227 DOI: 10.1177/1758835920930359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
375 Wang H, Li M, Tao X, Qian Y, Chen L, Tao G. ARHGEF39 promotes gastric cancer cell proliferation and migration via Akt signaling pathway. Mol Cell Biochem 2018;440:33-42. [PMID: 28871449 DOI: 10.1007/s11010-017-3153-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
376 Nishina T, Takano Y, Denda T, Yasui H, Takeda K, Ura T, Esaki T, Okuyama Y, Kondo K, Takahashi Y, Sugiyama Y, Muro K. A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients. Jpn J Clin Oncol 2013;43:1080-6. [PMID: 23999770 DOI: 10.1093/jjco/hyt127] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
377 Liu XF, Zhang H, Sun JQ, Yin C, Liu TF, Yang H, Chen LH. Correlation between expression of thymidylate synthase and clinical outcome of advanced gastric cancer treated with capecitabine alone chemotherapy. Tumour Biol 2014;35:12409-14. [PMID: 25185651 DOI: 10.1007/s13277-014-2557-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
378 Kano K, Sakamaki K, Oue N, Kimura Y, Hashimoto I, Hara K, Maezawa Y, Aoyama T, Fujikawa H, Hiroshima Y, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Cho H, Ito H, Shiozawa M, Yukawa N, Yoshikawa T, Morinaga S, Rino Y, Yasui W, Masuda M, Miyagi Y, Oshima T. Impact of the ESM-1 Gene Expression on Outcomes in Stage II/III Gastric Cancer Patients Who Received Adjuvant S-1 Chemotherapy. In Vivo 2020;34:461-7. [PMID: 31882514 DOI: 10.21873/invivo.11796] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
379 Kim JH, Park SR, Ryu MH, Ryoo BY, Kim KP, Kim BS, Yoo MW, Yook JH, Kim BS, Kim J. Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis. Cancer Res Treat. 2018;50:518-529. [PMID: 28546521 DOI: 10.4143/crt.2017.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
380 Oh SC. Update of adjuvant chemotherapy for resected gastric cancer. J Gastric Cancer. 2012;12:3-6. [PMID: 22500257 DOI: 10.5230/jgc.2012.12.1.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
381 Schirren R, Novotny A, Friess H, Reim D. Histopathologic Response Is a Positive Predictor of Overall Survival in Patients Undergoing Neoadjuvant/Perioperative Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Cancers-Analysis from a Large Single Center Cohort in Germany. Cancers (Basel) 2020;12:E2244. [PMID: 32796715 DOI: 10.3390/cancers12082244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
382 Cordero-García E, Ramos-Esquivel A, Alpízar-Alpízar W. Predictors of overall survival after surgery in gastric cancer patients from a Latin-American country. J Gastrointest Oncol 2018;9:64-72. [PMID: 29564172 DOI: 10.21037/jgo.2017.10.07] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
383 Leo S, Accettura C, Gnoni A, Licchetta A, Giampaglia M, Mauro A, Saracino V, Carr BI. Systemic treatment of gastrointestinal cancer in elderly patients. J Gastrointest Cancer. 2013;44:22-32. [PMID: 23150086 DOI: 10.1007/s12029-012-9447-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
384 Ema A, Yamashita K, Sakuramoto S, Wang G, Mieno H, Nemoto M, Shibata T, Katada N, Kikuchi S, Watanabe M. Lymph node ratio is a critical prognostic predictor in gastric cancer treated with S-1 chemotherapy. Gastric Cancer. 2014;17:67-75. [PMID: 23801337 DOI: 10.1007/s10120-013-0253-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
385 Hur H, Ham IH, Lee D, Jin H, Aguilera KY, Oh HJ, Han SU, Kwon JE, Kim YB, Ding K, Brekken RA. Discoidin domain receptor 1 activity drives an aggressive phenotype in gastric carcinoma. BMC Cancer 2017;17:87. [PMID: 28143619 DOI: 10.1186/s12885-017-3051-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
386 Lee JH, Kim JG, Jung HK, Kim JH, Jeong WK, Jeon TJ, Kim JM, Kim YI, Ryu KW, Kong SH, Kim HI, Jung HY, Kim YS, Zang DY, Cho JY, Park JO, Lim DH, Jung ES, Ahn HS, Kim HJ. Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer. 2014;14:87-104. [PMID: 25061536 DOI: 10.5230/jgc.2014.14.2.87] [Cited by in Crossref: 119] [Cited by in F6Publishing: 114] [Article Influence: 17.0] [Reference Citation Analysis]
387 Lee Y, Min SH, Park KB, Park YS, Kim JW, Ahn SH, Kim JW, Park DJ, Lee KW, Kim HH. Effect of Early Adjuvant Chemotherapy on Survival of Advanced Gastric Cancer Patients: a Propensity Score-matched Analysis. J Gastric Cancer. 2018;18:58-68. [PMID: 29629221 DOI: 10.5230/jgc.2018.18.e5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
388 Miceli R, Tomasello G, Bregni G, Bartolomeo MD, Pietrantonio F. Adjuvant chemotherapy for gastric cancer: Current evidence and future challenges. World J Gastroenterol 2014; 20(16): 4516-4525 [PMID: 24782604 DOI: 10.3748/wjg.v20.i16.4516] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
389 Feng XY, Chen YB, Wang W, Guan YX, Li YF, Chen S, Sun XW, Li W, Xu DZ, Zhan YQ, Zhang XS, Zhou ZW. Time-varying pattern of recurrence risk for gastric cancer patients. Med Oncol 2013;30:514. [PMID: 23436014 DOI: 10.1007/s12032-013-0514-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
390 Matsunaga T, Ishiguro R, Miyauchi W, Shishido Y, Miyatani K, Yamamoto M, Tokuyasu N, Takano S, Sakamoto T, Honjo S, Saito H, Fujiwara Y. Appraisal of long-time outcomes after curative surgery in elderly patients with gastric cancer: a propensity score matching analysis. BMC Surg 2021;21:33. [PMID: 33422067 DOI: 10.1186/s12893-021-01046-0] [Reference Citation Analysis]
391 Smyth EC, Cunningham D. Gastric cancer in 2012: Defining treatment standards and novel insights into disease biology. Nat Rev Clin Oncol 2013;10:73-4. [PMID: 23296114 DOI: 10.1038/nrclinonc.2012.228] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
392 Norton JA, Kim T, Kim J, McCarter MD, Kelly KJ, Wong J, Sicklick JK. SSAT State-of-the-Art Conference: Current Surgical Management of Gastric Tumors. J Gastrointest Surg 2018;22:32-42. [PMID: 28808875 DOI: 10.1007/s11605-017-3533-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
393 Kelly KJ, Selby L, Chou JF, Dukleska K, Capanu M, Coit DG, Brennan MF, Strong VE. Laparoscopic Versus Open Gastrectomy for Gastric Adenocarcinoma in the West: A Case-Control Study. Ann Surg Oncol 2015;22:3590-6. [PMID: 25631063 DOI: 10.1245/s10434-015-4381-y] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 13.0] [Reference Citation Analysis]
394 Sun Z, Chen H, Han Z, Huang W, Hu Y, Zhao M, Lin T, Yu J, Liu H, Jiang Y, Li G. Genomics Score Based on Genome-Wide Network Analysis for Prediction of Survival in Gastric Cancer: A Novel Prognostic Signature. Front Genet 2020;11:835. [PMID: 32849822 DOI: 10.3389/fgene.2020.00835] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
395 Xu W, Wang S, Chen Q, Zhang Y, Ni P, Wu X, Zhang J, Qiang F, Li A, Røe OD, Xu S, Wang M, Zhang R, Zhou J. TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer. Cell Death Dis 2014;5:e1055. [PMID: 24525731 DOI: 10.1038/cddis.2014.27] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
396 Qian J, Qian Y, Wang J, Gu B, Pei D, He S, Zhu F, Røe OD, Xu J, Liu L, Gu Y, Guo R, Yin Y, Shu Y, Chen X. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy. Drug Des Devel Ther 2016;10:241-58. [PMID: 26966350 DOI: 10.2147/DDDT.S88743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
397 Lin S, Yue J, Guan X, Yuan P, Wang J, Luo Y, Fan Y, Cai R, Li Q, Chen S, Zhang P, Li Q, Ma F, Xu B. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer. Cancer Commun (Lond) 2019;39:57. [PMID: 31601265 DOI: 10.1186/s40880-019-0399-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
398 Wang X, He H, Zhang H, Chen W, Ji Y, Tang Z, Fang Y, Wang C, Liu F, Shen Z, Qin J, Zhu Y, Liu H, Xu J, Gu J, Qin X, Sun Y. Clinical and prognostic implications of β1, 6-N-acetylglucosaminyltransferase V in patients with gastric cancer. Cancer Sci 2013;104:185-93. [PMID: 23107376 DOI: 10.1111/cas.12049] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
399 Chen Y, Xia X, Wang S, Wu X, Zhang J, Zhou Y, Tan Y, He S, Qiang F, Li A, Røe OD, Zhou J. High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients. J Gastroenterol 2013;48:1034-44. [PMID: 23307041 DOI: 10.1007/s00535-012-0724-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
400 Kurokawa Y, Sasako M, Sano T, Yoshikawa T, Iwasaki Y, Nashimoto A, Ito S, Kurita A, Mizusawa J, Nakamura K; Japan Clinical Oncology Group (JCOG9502). Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. Br J Surg. 2015;102:341-348. [PMID: 25605628 DOI: 10.1002/bjs.9764] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 9.3] [Reference Citation Analysis]
401 Song F, Wang H, Wang Y. Myeloid ecotropic viral integration site 1 inhibits cell proliferation, invasion or migration in human gastric cancer. Oncotarget 2017;8:90050-60. [PMID: 29163810 DOI: 10.18632/oncotarget.21376] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
402 Zheng Y, Li Y, Liu X, Sun H, Wang Z, Zhang R. Reevaluation of Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials Over the Past 20 Years. Medicine (Baltimore) 2015;94:e1102. [PMID: 26166100 DOI: 10.1097/MD.0000000000001102] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
403 Chen YH, Xiao J, Chen XJ, Wang HS, Liu D, Xiang J, Peng JS. Nomogram for predicting pathological complete response to neoadjuvant chemotherapy in patients with advanced gastric cancer. World J Gastroenterol 2020; 26(19): 2427-2439 [PMID: 32476803 DOI: 10.3748/wjg.v26.i19.2427] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
404 Li Q, Wang G, Wang H. miR-126 Functions as a Tumor Suppressor by Targeting SRPK1 in Human Gastric Cancer. Oncol Res 2018;26:1345-53. [PMID: 29510776 DOI: 10.3727/096504018X15180508535835] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
405 Cravo M, Fidalgo C, Garrido R, Rodrigues T, Luz G, Palmela C, Santos M, Lopes F, Maio R. Towards curative therapy in gastric cancer: Faraway, so close!. World J Gastroenterol 2015; 21(41): 11609-11620 [PMID: 26556990 DOI: 10.3748/wjg.v21.i41.11609] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
406 Schirren R, Reim D, Novotny AR. Adjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review. Ther Adv Med Oncol. 2015;7:39-48. [PMID: 25553082 DOI: 10.1177/1758834014558839] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
407 Lin JX, Desiderio J, Lin JP, Wang W, Tu RH, Li P, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Zheng CH, Zhou ZW, Parisi A, Huang CM. Multicenter Validation Study of the American Joint Commission on Cancer (8th Edition) for Gastric Cancer: Proposal for a Simplified and Improved TNM Staging System. J Cancer 2020;11:3483-91. [PMID: 32284744 DOI: 10.7150/jca.36891] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
408 Lee J, An JY, Choi MG, Park SH, Kim ST, Lee JH, Sohn TS, Bae JM, Kim S, Lee H, Min BH, Kim JJ, Jeong WK, Choi DI, Kim KM, Kang WK, Kim M, Seo SW. Deep Learning-Based Survival Analysis Identified Associations Between Molecular Subtype and Optimal Adjuvant Treatment of Patients With Gastric Cancer. JCO Clin Cancer Inform 2018;2:1-14. [PMID: 30652558 DOI: 10.1200/CCI.17.00065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
409 Li N, Wang X, Tang Y, Zhao D, Chi Y, Yang L, Jiang L, Jiang J, Liu W, Tang Y, Fang H, Liu Y, Song Y, Wang S, Jin J, Li Y. A prospective phase I study of hypo-fractionated neoadjuvant radiotherapy for locally advanced gastric cancer. BMC Cancer 2018;18:803. [PMID: 30089457 DOI: 10.1186/s12885-018-4707-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
410 Woo Y, Goldner B, Ituarte P, Lee B, Melstrom L, Son T, Noh SH, Fong Y, Hyung WJ. Lymphadenectomy with Optimum of 29 Lymph Nodes Retrieved Associated with Improved Survival in Advanced Gastric Cancer: A 25,000-Patient International Database Study. J Am Coll Surg 2017;224:546-55. [PMID: 28017807 DOI: 10.1016/j.jamcollsurg.2016.12.015] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
411 Li P, He HQ, Zhu CM, Ling YH, Hu WM, Zhang XK, Luo RZ, Yun JP, Xie D, Li YF, Cai MY. The prognostic significance of lymphovascular invasion in patients with resectable gastric cancer: a large retrospective study from Southern China. BMC Cancer 2015;15:370. [PMID: 25947284 DOI: 10.1186/s12885-015-1370-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
412 Yazawa T, Hori T, Yamamoto H, Harada H, Yamamoto M, Yamada M, Tani M, Sato A, Kamada Y, Tani R, Aoyama R, Sasaki Y, Zaima M. Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience. World J Gastrointest Pharmacol Ther 2020; 11(5): 110-122 [PMID: 33251035 DOI: 10.4292/wjgpt.v11.i5.110] [Reference Citation Analysis]
413 Tseng LL, Cheng HH, Yeh TS, Huang SC, Syu YY, Chuu CP, Yuh CH, Kung HJ, Wang WC. Targeting the histone demethylase PHF8-mediated PKCα-Src-PTEN axis in HER2-negative gastric cancer. Proc Natl Acad Sci U S A 2020;117:24859-66. [PMID: 32958674 DOI: 10.1073/pnas.1919766117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
414 Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, Wang C, Qiu MZ, Cai MY, Wu Q, Liu H, Guan WL, Zhou AP, Zhang YJ, Liu TS, Bi F, Yuan XL, Rao SX, Xin Y, Sheng WQ, Xu HM, Li GX, Ji JF, Zhou ZW, Liang H, Zhang YQ, Jin J, Shen L, Li J, Xu RH. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond) 2021;41:747-95. [PMID: 34197702 DOI: 10.1002/cac2.12193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
415 Chen S, Lao J, Geng Q, Zhang J, Wu A, Xu D. A 3-MicroRNA Signature Identified From Serum Predicts Clinical Outcome of the Locally Advanced Gastric Cancer. Front Oncol 2020;10:565. [PMID: 32656071 DOI: 10.3389/fonc.2020.00565] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
416 Hosoda K, Yamashita K, Moriya H, Mieno H, Watanabe M. Optimal treatment for Siewert type II and III adenocarcinoma of the esophagogastric junction: A retrospective cohort study with long-term follow-up. World J Gastroenterol 2017; 23(15): 2723-2730 [PMID: 28487609 DOI: 10.3748/wjg.v23.i15.2723] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
417 Liu Z, Wang Y, Shan F, Ying X, Zhang Y, Li S, Jia Y, Li Z, Ji J. 5-Fu-Based Doublet Regimen in Patients Receiving Perioperative or Postoperative Chemotherapy for Locally Advanced Gastric Cancer: When to Start and How Long Should the Regimen Last? Cancer Manag Res 2021;13:147-61. [PMID: 33469359 DOI: 10.2147/CMAR.S285361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
418 Wei G, Wu M, Zhu H, Han S, Chen J, Zhai C, Shi L. Off-Label Use of Antineoplastic Drugs to Treat Malignancies: Evidence From China Based on a Nationwide Medical Insurance Data Analysis. Front Pharmacol 2021;12:616453. [PMID: 33897416 DOI: 10.3389/fphar.2021.616453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
419 Liu SF, Lu CR, Cheng HD, Xi HQ, Cui JX, Li JY, Shen WS, Chen L. Comparison of Therapeutic Efficacy between Gastrectomy with Transarterial Chemoembolization Plus Systemic Chemotherapy and Systemic Chemotherapy Alone in Gastric Cancer with Synchronous Liver Metastasis. Chin Med J (Engl). 2015;128:2194-2201. [PMID: 26265613 DOI: 10.4103/0366-6999.162497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
420 Zhou ML, Li GC, Yang W, Deng WJ, Hu R, Wang Y, Long ZW, Liu XW, Wang YN, Zhang Z. Adjuvant chemoradiotherapy versus adjuvant chemotherapy for R1 resected gastric cancer: a retrospective cohort study. Br J Radiol 2018;91:20180276. [PMID: 29906235 DOI: 10.1259/bjr.20180276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
421 Qu JL, Li X, Qu XJ, Zhu ZT, Zhou LZ, Teng YE, Zhang JD, Jin B, Zhao MF, Yu P, Liu YP. Optimal duration of fluorouracil-based adjuvant chemotherapy for patients with resectable gastric cancer. PLoS One 2013;8:e83196. [PMID: 24386161 DOI: 10.1371/journal.pone.0083196] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
422 Li B, Wong IY, Chan FS, Chan KK, Wong CL, Law TT, Kwok JY, Lo AWI, Law S. Impact of Extracapsular Extension of Lymph Node in Adenocarcinoma of the Stomach. Ann Surg Oncol 2020;27:4225-32. [PMID: 32372311 DOI: 10.1245/s10434-020-08541-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
423 Shan Z, Wang W, Tong Y, Zhang J. Genome-Scale Analysis Identified NID2, SPARC, and MFAP2 as Prognosis Markers of Overall Survival in Gastric Cancer. Med Sci Monit 2021;27:e929558. [PMID: 33758160 DOI: 10.12659/MSM.929558] [Reference Citation Analysis]
424 Hayashi M, Yoshikawa T, Yura M, Otsuki S, Yamagata Y, Morita S, Katai H, Nishida T. Predictive value of the surgical Apgar score on postoperative complications in advanced gastric cancer patients treated with neoadjuvant chemotherapy followed by radical gastrectomy: a single-center retrospective study. BMC Surg 2020;20:150. [PMID: 32652977 DOI: 10.1186/s12893-020-00813-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
425 Yang Y, Qu A, Zhao R, Hua M, Zhang X, Dong Z, Zheng G, Pan H, Wang H, Yang X, Zhang Y. Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer. Mol Oncol. 2018;12:2072-2084. [PMID: 30242969 DOI: 10.1002/1878-0261.12385] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
426 Lu J, Cao LL, Li P, Xie JW, Wang JB, Lin JX, Chen QY, Lin M, Tu RH, Huang CM, Zheng CH. Significance of Preoperative Systemic Immune Score for Stage I Gastric Cancer Patients. Gastroenterol Res Pract 2018;2018:3249436. [PMID: 30116261 DOI: 10.1155/2018/3249436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
427 Zhao JH, Gao P, Song YX, Sun JX, Chen XW, Ma B, Yang YC, Wang ZN. Which is better for gastric cancer patients, perioperative or adjuvant chemotherapy: a meta-analysis. BMC Cancer 2016;16:631. [PMID: 27519527 DOI: 10.1186/s12885-016-2667-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
428 Segami K, Aoyama T, Hiroshima Y, Komori K, Hashimoto I, Watanabe H, Kano K, Nagasawa S, Nakazono M, Maezawa Y, Fujikawa H, Numata M, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Siozawa M, Yukawa N, Morinaga S, Rino Y, Masuda M, Miyagi Y, Saeki H, Oshima T. Clinical Significance of TAP1 and DLL4 Expression in Patients With Locally Advanced Gastric Cancer. In Vivo 2021;35:2771-7. [PMID: 34410967 DOI: 10.21873/invivo.12562] [Reference Citation Analysis]
429 Bi J, Bai Z, Ma X, Song J, Guo Y, Zhao J, Yi X, Han S, Zhang Z. Txr1: an important factor in oxaliplatin resistance in gastric cancer. Med Oncol 2014;31:807. [PMID: 24362794 DOI: 10.1007/s12032-013-0807-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
430 Pan QX, Su ZJ, Zhang JH, Wang CR, Ke SY. A comparison of the prognostic value of preoperative inflammation-based scores and TNM stage in patients with gastric cancer. Onco Targets Ther. 2015;8:1375-1385. [PMID: 26124667 DOI: 10.2147/ott.s82437] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 6.3] [Reference Citation Analysis]
431 Wang Y, Wang C, Xiao H, Niu C, Wu H, Jin H, Yao C, He H, Tian H, Han F, Li D, Han W, Xu J, Chen J, Cui J, Li W. Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer. Cancer Med 2017;6:45-53. [PMID: 27790867 DOI: 10.1002/cam4.942] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
432 Miwa T, Kanda M, Umeda S, Tanaka H, Shimizu D, Tanaka C, Kobayashi D, Hayashi M, Yamada S, Nakayama G, Koike M, Kodera Y. Establishment of Peritoneal and Hepatic Metastasis Mouse Xenograft Models Using Gastric Cancer Cell Lines. In Vivo 2019;33:1785-92. [PMID: 31662503 DOI: 10.21873/invivo.11669] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
433 Huang W, Zhan D, Li Y, Zheng N, Wei X, Bai B, Zhang K, Liu M, Zhao X, Ni X, Xia X, Shi J, Zhang C, Lu Z, Ji J, Wang J, Wang S, Ji G, Li J, Nie Y, Liang W, Wu X, Cui J, Meng Y, Cao F, Shi T, Zhu W, Wang Y, Chen L, Zhao Q, Wang H, Shen L, Qin J. Proteomics provides individualized options of precision medicine for patients with gastric cancer. Sci China Life Sci 2021;64:1199-211. [PMID: 34258712 DOI: 10.1007/s11427-021-1966-4] [Reference Citation Analysis]
434 Cao GJ, Wang D, Zeng ZP, Wang GX, Hu CJ, Xing ZF. Direct interaction between Rab5a and Rab4a enhanced epidermal growth factor-stimulated proliferation of gastric cancer cells. World J Gastrointest Oncol 2021; 13(10): 1492-1505 [PMID: 34721780 DOI: 10.4251/wjgo.v13.i10.1492] [Reference Citation Analysis]
435 Chen Y, Lin WS, Zhu WF, Lin J, Zhou ZF, Huang CZ, Chen G, Shi Y, Guo ZQ, Ye YB. Tumor MICA status predicts the efficacy of immunotherapy with cytokine-induced killer cells for patients with gastric cancer. Immunol Res 2016;64:251-9. [PMID: 26607264 DOI: 10.1007/s12026-015-8743-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
436 León-Espinoza C, López-Mozos F, Marti-Obiol R, Garces-Albir M, Ortega-Serrano J. “Magic” of our gastric cancer results on perioperative chemotherapy. World J Gastrointest Pathophysiol 2016; 7(3): 283-287 [PMID: 27574566 DOI: 10.4291/wjgp.v7.i3.283] [Reference Citation Analysis]
437 Yuan LW, Yamashita H, Seto Y. Glucose metabolism in gastric cancer: The cutting-edge. World J Gastroenterol 2016; 22(6): 2046-2059 [PMID: 26877609 DOI: 10.3748/wjg.v22.i6.2046] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 41] [Article Influence: 7.8] [Reference Citation Analysis]
438 Wang X, Li X, Zhou N, Zhong D, Bai C, Zhao L. Graded histologic response after neoadjuvant chemotherapy is an optimal criterion for treatment change in patients with locally advanced gastric cancer. Ann Transl Med 2019;7:546. [PMID: 31807528 DOI: 10.21037/atm.2019.09.82] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
439 Jeong JW, Kwon IG, Son YG, Ryu SW. Could Adjuvant Chemotherapy after Surgery Benefit Elderly Patients with Advanced Gastric Cancer? J Gastric Cancer. 2016;16:260-265. [PMID: 28053813 DOI: 10.5230/jgc.2016.16.4.260] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
440 Newton AD, Datta J, Loaiza-Bonilla A, Karakousis GC, Roses RE. Neoadjuvant therapy for gastric cancer: current evidence and future directions. J Gastrointest Oncol. 2015;6:534-543. [PMID: 26487948 DOI: 10.3978/j.issn.2078-6891.2015.047] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
441 Voron T, Messager M, Duhamel A, Lefevre J, Mabrut JY, Goere D, Meunier B, Brigand C, Hamy A, Glehen O, Mariette C, Paye F. Is signet-ring cell carcinoma a specific entity among gastric cancers? Gastric Cancer. 2016;19:1027-1040. [PMID: 26606931 DOI: 10.1007/s10120-015-0564-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 34] [Article Influence: 4.2] [Reference Citation Analysis]
442 Hoang T, Park M, Hiyama D, Dayyani F. Predictors of outcomes in patients with gastric cancer treated with contemporary multimodality strategies-a single institution experience. J Gastrointest Oncol 2020;11:411-20. [PMID: 32399281 DOI: 10.21037/jgo.2019.01.08] [Reference Citation Analysis]
443 Chen L, Hao Y, Cong X, Zou M, Li S, Zhu L, Song H, Xue Y. Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy. Technol Cancer Res Treat 2019;18:1533033819829485. [PMID: 30760114 DOI: 10.1177/1533033819829485] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
444 Che K, Wang Y, Wu N, Liu Q, Yang J, Liu B, Wei J. Prognostic Nomograms Based on Three Lymph Node Classification Systems for Resected Gastric Adenocarcinoma: A Large Population-Based Cohort Study and External Validation. Ann Surg Oncol 2021. [PMID: 34241748 DOI: 10.1245/s10434-021-10299-1] [Reference Citation Analysis]
445 Kersting S, Konopke R, Dittert D, Distler M, Rückert F, Gastmeier J, Baretton GB, Saeger HD. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma? J Gastroenterol Hepatol 2009;24:886-95. [PMID: 19655439 DOI: 10.1111/j.1440-1746.2008.05732.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
446 Chang SC, Tang CM, Le PH, Kuo CJ, Chen TH, Wang SY, Chou WC, Chen TC, Yeh TS, Hsu JT. Impact of Pancreatic Resection on Survival in Locally Advanced Resectable Gastric Cancer. Cancers (Basel) 2021;13:1289. [PMID: 33799426 DOI: 10.3390/cancers13061289] [Reference Citation Analysis]
447 Bauer K, Schroeder M, Porzsolt F, Henne-Bruns D. Comparison of international guidelines on the accompanying therapy for advanced gastric cancer: reasons for the differences. J Gastric Cancer. 2015;15:10-18. [PMID: 25861518 DOI: 10.5230/jgc.2015.15.1.10] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
448 Wang FH, Shen L, Li J, Zhou ZW, Liang H, Zhang XT, Tang L, Xin Y, Jin J, Zhang YJ, Yuan XL, Liu TS, Li GX, Wu Q, Xu HM, Ji JF, Li YF, Wang X, Yu S, Liu H, Guan WL, Xu RH. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond). 2019;39:10. [PMID: 30885279 DOI: 10.1186/s40880-019-0349-9] [Cited by in Crossref: 123] [Cited by in F6Publishing: 115] [Article Influence: 61.5] [Reference Citation Analysis]
449 Cui H, Cui JX, Wang YN, Cao B, Deng H, Zhang KC, Xie TY, Liang WQ, Liu Y, Chen L, Wei B. Could neoadjuvant chemotherapy increase postoperative complication risk of laparoscopic total gastrectomy? A mono-institutional propensity score-matched study in China. World J Gastrointest Surg 2021; 13(5): 429-442 [PMID: 34122733 DOI: 10.4240/wjgs.v13.i5.429] [Reference Citation Analysis]
450 Wang JB, Li P, Liu XL, Zheng QL, Ma YB, Zhao YJ, Xie JW, Lin JX, Lu J, Chen QY, Cao LL, Lin M, Liu LC, Lian NZ, Yang YH, Huang CM, Zheng CH. An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer. Nat Commun 2020;11:6352. [PMID: 33311518 DOI: 10.1038/s41467-020-20260-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
451 Merrett ND. Multimodality treatment of potentially curative gastric cancer: Geographical variations and future prospects. World J Gastroenterol 2014; 20(36): 12892-12899 [PMID: 25278686 DOI: 10.3748/wjg.v20.i36.12892] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
452 Goetze TO, Al-Batran SE, Berlth F, Hoelscher AH. Multimodal Treatment Strategies in Esophagogastric Junction Cancer: a Western Perspective. J Gastric Cancer 2019;19:148-56. [PMID: 31245159 DOI: 10.5230/jgc.2019.19.e19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
453 Turgeon MK, Gamboa AC, Rupji M, Lee RM, Switchenko JM, El-Rayes BF, Russell MC, Cardona K, Kooby DA, Staley CA, Maithel SK, Shah MM. Should Signet Ring Cell Histology Alter the Treatment Approach for Clinical Stage I Gastric Cancer? Ann Surg Oncol 2021;28:97-105. [PMID: 32524459 DOI: 10.1245/s10434-020-08714-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
454 Fujitani K, Kurokawa Y, Takeno A, Endoh S, Ohmori T, Fujita J, Yamasaki M, Takiguchi S, Mori M, Doki Y; Osaka University Clinical Research Group for Gastroenterological Surgery. Time to initiation or duration of S-1 adjuvant chemotherapy; which really impacts on survival in stage II and III gastric cancer? Gastric Cancer 2018;21:446-52. [PMID: 28965205 DOI: 10.1007/s10120-017-0767-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
455 Lieto E, Auricchio A, Tirino G, Pompella L, Panarese I, Del Sorbo G, Ferraraccio F, De Vita F, Galizia G, Cardella F. Naples Prognostic Score Predicts Tumor Regression Grade in Resectable Gastric Cancer Treated with Preoperative Chemotherapy. Cancers (Basel) 2021;13:4676. [PMID: 34572903 DOI: 10.3390/cancers13184676] [Reference Citation Analysis]
456 Wang J, Yang M, Wang Q, Ji G. Comparison of Early Oral Feeding With Traditional Oral Feeding After Total Gastrectomy for Gastric Cancer: A Propensity Score Matching Analysis. Front Oncol 2019;9:1194. [PMID: 31788451 DOI: 10.3389/fonc.2019.01194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
457 Oh DY, Bang YJ. Adjuvant and neoadjuvant therapy for gastric cancer. Curr Treat Options Oncol. 2013;14:311-320. [PMID: 23686725 DOI: 10.1007/s11864-013-0238-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
458 Park YS, Shin DJ, Son SY, Kim KH, Park DJ, Ahn SH, Park DJ, Kim HH. Roux Stasis Syndrome and Gastric Food Stasis After Laparoscopic Distal Gastrectomy with Uncut Roux-en-Y Reconstruction in Gastric Cancer Patients: A Propensity Score Matching Analysis. World J Surg. 2018;42:4022-4032. [PMID: 29915987 DOI: 10.1007/s00268-018-4715-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
459 Ren DF, Zheng FC, Zhao JH, Shen GS, Ahmad R, Zhang SS, Zhang Y, Kan J, Dong L, Wang ZY, Zhao FX, Zhao JD. Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study. World J Clin Cases 2018; 6(10): 373-383 [PMID: 30283800 DOI: 10.12998/wjcc.v6.i10.373] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
460 Proserpio I, Rausei S, Barzaghi S, Frattini F, Galli F, Iovino D, Rovera F, Boni L, Dionigi G, Pinotti G. Multimodal treatment of gastric cancer. World J Gastrointest Surg 2014; 6(4): 55-58 [PMID: 24829622 DOI: 10.4240/wjgs.v6.i4.55] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
461 Wang X, Jin J, Li YX, Ren H, Fang H, Wang SL, Liu YP, Wang WH, Yu ZH, Song YW, Liu XF. Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer. World J Gastroenterol 2014; 20(4): 1067-1073 [PMID: 24574780 DOI: 10.3748/wjg.v20.i4.1067] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
462 Wang YN, Chang SY, Hwang JM, Chang YK, Kao WY, Wan HL, Tzeng IS, Wu CC. Evaluating the benefit of adjuvant radiotherapy after extensive lymph node dissection for gastric cancer: a single-institute retrospective study. Tzu Chi Med J 2021;33:288-93. [PMID: 34386368 DOI: 10.4103/tcmj.tcmj_230_20] [Reference Citation Analysis]
463 Wang X, Wang WH, Wang SL, Song YW, Liu YP, Tang Y, Li N, Liu WY, Fang H, Li YX, Zhao DB, Chi Y, Yang L, Jin J. Efficacy and toxicity of capecitabine combined with intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with gastric cancer. World J Gastrointest Oncol 2021; 13(10): 1532-1543 [PMID: 34721783 DOI: 10.4251/wjgo.v13.i10.1532] [Reference Citation Analysis]
464 Stahl KA, Olecki EJ, Dixon ME, Peng JS, Torres MB, Gusani NJ, Shen C. Gastric Cancer Treatments and Survival Trends in the United States. Curr Oncol 2020;28:138-51. [PMID: 33704182 DOI: 10.3390/curroncol28010017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
465 Lu J, Xu BB, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Chen QY, Truty MJ, Huang CM. Development and External Validation of a Nomogram to Predict Recurrence-Free Survival After R0 Resection for Stage II/III Gastric Cancer: An International Multicenter Study. Front Oncol 2020;10:574611. [PMID: 33194683 DOI: 10.3389/fonc.2020.574611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
466 Harada K, Mizrak Kaya D, Shimodaira Y, Ajani JA. Global chemotherapy development for gastric cancer. Gastric Cancer 2017;20:92-101. [PMID: 27718136 DOI: 10.1007/s10120-016-0655-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
467 Wang G, Yang B, Fu Z, Wang X, Zhang Z. Efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of gastric cancer: a meta-analysis of randomized controlled trials. Int J Clin Oncol 2019;24:614-23. [PMID: 30919257 DOI: 10.1007/s10147-019-01425-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
468 Miao RL, Wu AW. Towards personalized perioperative treatment for advanced gastric cancer. World J Gastroenterol 2014; 20(33): 11586-11594 [PMID: 25206266 DOI: 10.3748/wjg.v20.i33.11586] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
469 Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643-655. [PMID: 24061039 DOI: 10.1038/nrclinonc.2013.170] [Cited by in Crossref: 249] [Cited by in F6Publishing: 241] [Article Influence: 31.1] [Reference Citation Analysis]
470 Nakanishi K, Kanda M, Ito S, Mochizuki Y, Teramoto H, Ishigure K, Murai T, Asada T, Ishiyama A, Matsushita H, Tanaka C, Kobayashi D, Fujiwara M, Murotani K, Kodera Y. Delay in initiation of postoperative adjuvant chemotherapy with S-1 monotherapy and prognosis for gastric cancer patients: analysis of a multi-institutional dataset. Gastric Cancer. 2019;22:1215-1225. [PMID: 30955110 DOI: 10.1007/s10120-019-00961-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
471 Kitayama J, Ishigami H, Yamaguchi H, Emoto S, Watanabe T. Intraperitoneal Paclitaxel is useful as adjuvant chemotherapy for advanced gastric cancer with serosal exposure. Case Rep Oncol 2014;7:58-64. [PMID: 24575018 DOI: 10.1159/000358379] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
472 Aoyama T, Yoshikawa T, Miyagi Y, Kameda Y, Shirai J, Hayashi T, Cho H, Oshima T, Yukawa N, Rino Y, Masuda M, Tsuburaya A. Human epidermal growth factor receptor 2 (Her-2) and S-1 adjuvant chemotherapy in stage 2/3 gastric cancer patients who underwent D2 gastrectomy. Surg Today 2013;43:1390-7. [PMID: 23512532 DOI: 10.1007/s00595-013-0544-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
473 Chen L, Zuo Y, Zhu L, Zhang Y, Li S, Ma F, Han Y, Song H, Xue Y. Peripheral venous blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy. Onco Targets Ther 2017;10:2569-80. [PMID: 28553122 DOI: 10.2147/OTT.S134716] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
474 Lin J, Zhao Y, Zhou Y, Tian Y, He Q, Lin J, Hao H, Zou B, Jiang L, Zhao G, Lin W, Xu Y, Li Z, Xue F, Li S, Fu W, Li Y, Xu Z, Li Y, Chen J, Zhou X, Zhu Z, Cai L, Li E, Li H, Zheng C, Li P, Huang C, Xie J. Comparison of Survival and Patterns of Recurrence in Gastric Neuroendocrine Carcinoma, Mixed Adenoneuroendocrine Carcinoma, and Adenocarcinoma. JAMA Netw Open 2021;4:e2114180. [PMID: 34313744 DOI: 10.1001/jamanetworkopen.2021.14180] [Reference Citation Analysis]
475 Nishibeppu K, Komatsu S, Ichikawa D, Imamura T, Kosuga T, Okamoto K, Konishi H, Shiozaki A, Fujiwara H, Otsuji E. Venous invasion as a risk factor for recurrence after gastrectomy followed by chemotherapy for stage III gastric cancer. BMC Cancer 2018;18:108. [PMID: 29382310 DOI: 10.1186/s12885-018-4052-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
476 Quéro L, Guillerm S, Hennequin C. Neoadjuvant or adjuvant therapy for gastric cancer. World J Gastrointest Oncol 2015; 7(8): 102-110 [PMID: 26306142 DOI: 10.4251/wjgo.v7.i8.102] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
477 Lee J, Sohn I, Do IG, Kim KM, Park SH, Park JO, Park YS, Lim HY, Sohn TS, Bae JM, Choi MG, Lim DH, Min BH, Lee JH, Rhee PL, Kim JJ, Choi DI, Tan IB, Das K, Tan P, Jung SH, Kang WK, Kim S. Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery. PLoS One. 2014;9:e90133. [PMID: 24598828 DOI: 10.1371/journal.pone.0090133] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 8.6] [Reference Citation Analysis]
478 Desai AM, Lichtman SM. Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly. Cancer Biol Med. 2015;12:284-291. [PMID: 26779365 DOI: 10.7497/j.issn.2095-3941.2015.0078] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
479 Squires MH 3rd, Fisher SB, Fisher KE, Patel SH, Kooby DA, El-Rayes BF, Staley CA 3rd, Farris AB 3rd, Maithel SK. Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma. Cancer 2013;119:3242-50. [PMID: 23719746 DOI: 10.1002/cncr.28175] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
480 Zhou Y, Yu F, Wu L, Ye F, Zhang L, Li Y. Survival after Gastrectomy in Node-Negative Gastric Cancer: A Review and Meta-Analysis of Prognostic Factors. Med Sci Monit 2015;21:1911-9. [PMID: 26134762 DOI: 10.12659/MSM.893856] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
481 Brenkman HJ, Haverkamp L, Ruurda JP, van Hillegersberg R. Worldwide practice in gastric cancer surgery. World J Gastroenterol 2016; 22(15): 4041-4048 [PMID: 27099448 DOI: 10.3748/wjg.v22.i15.4041] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 35] [Article Influence: 7.4] [Reference Citation Analysis]
482 Peng C, Liu J, Yang G, Li Y. Lysyl oxidase activates cancer stromal cells and promotes gastric cancer progression: quantum dot-based identification of biomarkers in cancer stromal cells. Int J Nanomedicine 2018;13:161-74. [PMID: 29343955 DOI: 10.2147/IJN.S143871] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
483 Hsieh MC, Wang SH, Wei CT, Chen CY, Chen YY, Pei SN, Tsai YF, Rau KM. S1 versus Doublet Regimens as Adjuvant Chemotherapy in Patients with Advanced Gastric Cancer after Radical Surgery with D2 Dissection-A Propensity Score Matching Analysis. Cancers (Basel) 2020;12:E2384. [PMID: 32842507 DOI: 10.3390/cancers12092384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
484 Ojetti V, Persiani R, Cananzi FC, Sensi C, Piscaglia AC, Saulnier N, Biondi A, Gasbarrini A, D'Ugo D. cDNA-microarray analysis as a new tool to predict lymph node metastasis in gastric cancer. World J Surg. 2014;38:2058-2064. [PMID: 24696059 DOI: 10.1007/s00268-014-2529-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
485 Wang H, Wang C, Tian W, Yao Y. The crucial role of SRPK1 in IGF-1-induced EMT of human gastric cancer. Oncotarget 2017;8:72157-66. [PMID: 29069776 DOI: 10.18632/oncotarget.20048] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
486 Wang X, Zhao DB, Yang L, Chi Y, Tang Y, Li N, Wang SL, Song YW, Liu YP, Liu WY, Ren H, Zhang T, Wang JY, Chen XS, Fang H, Wang WH, Li YX, Jin J. S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study. Br J Cancer 2018;118:338-43. [PMID: 29235569 DOI: 10.1038/bjc.2017.424] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
487 Futsukaichi T, Etoh T, Nakajima K, Daa T, Shiroshita H, Shiraishi N, Kitano S, Inomata M. Decreased expression of Bauhinia purpurea lectin is a predictor of gastric cancer recurrence. Surg Today 2015;45:1299-306. [PMID: 25753302 DOI: 10.1007/s00595-015-1127-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
488 Shin HB, Lee SH, Son YG, Ryu SW, Sohn SS. Chemoresponse after non-curative gastrectomy for M1 gastric cancer. World J Surg Oncol. 2015;13:13. [PMID: 25634223 DOI: 10.1186/s12957-015-0447-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
489 Jácome AA, Coutinho AK, Lima EM, Andrade AC, Santos JSD. Personalized medicine in gastric cancer: Where are we and where are we going? World J Gastroenterol 2016; 22(3): 1160-1171 [PMID: 26811654 DOI: 10.3748/wjg.v22.i3.1160] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
490 Kim SG, Hwang SH. The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer. World J Surg Oncol 2016;14:102. [PMID: 27039375 DOI: 10.1186/s12957-016-0845-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
491 Chen K, Pan Y, Zhai ST, Cai JQ, Chen QL, Chen DW, Zhu YP, Zhang Y, Zhang YP, Maher H, Wang XF. Laparoscopic gastrectomy in obese gastric cancer patients: a comparative study with non-obese patients and evaluation of difference in laparoscopic methods. BMC Gastroenterol. 2017;17:78. [PMID: 28629379 DOI: 10.1186/s12876-017-0638-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
492 Petrelli F, Zaniboni A, Coinu A, Cabiddu M, Ghilardi M, Sgroi G, Barni S. Cisplatin or not in advanced gastric cancer: a systematic review and meta-analysis. PLoS One 2013;8:e83022. [PMID: 24386137 DOI: 10.1371/journal.pone.0083022] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
493 Jiang Y, Chen C, Xie J, Wang W, Zha X, Lv W, Chen H, Hu Y, Li T, Yu J, Zhou Z, Xu Y, Li G. Radiomics signature of computed tomography imaging for prediction of survival and chemotherapeutic benefits in gastric cancer. EBioMedicine. 2018;36:171-182. [PMID: 30224313 DOI: 10.1016/j.ebiom.2018.09.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 18.3] [Reference Citation Analysis]
494 Tsai CY, Lin TA, Huang SC, Hsu JT, Yeh CN, Chen TC, Chiu CT, Chen JS, Yeh TS. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched. Oncologist 2020;25:e1021-30. [PMID: 32058649 DOI: 10.1634/theoncologist.2019-0419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
495 Kim YW, Joo J, Yoon HM, Eom BW, Ryu KW, Choi IJ, Kook MC, Schuhmacher C, Siewert JR, Reim D. Different survival outcomes after curative R0-resection for Eastern Asian and European gastric cancer: Results from a propensity score matched analysis comparing a Korean and a German specialized center. Medicine (Baltimore) 2016;95:e4261. [PMID: 27428238 DOI: 10.1097/MD.0000000000004261] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
496 Ji X, Yang Q, Qin H, Zhou J, Liu W. Tumor blood supply may predict neoadjuvant chemotherapy response and survival in patients with gastric cancer. J Int Med Res. 2019;47:2524-2532. [PMID: 31039658 DOI: 10.1177/0300060519845491] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
497 Namikawa T, Ishida N, Tsuda S, Fujisawa K, Munekage E, Iwabu J, Munekage M, Uemura S, Tsujii S, Maeda H, Kitagawa H, Kobayashi M, Hanazaki K. Pathological Complete Response by S-1 Chemotherapy in Advanced Gastric Cancer. In Vivo 2018;32:1211-6. [PMID: 30150446 DOI: 10.21873/invivo.11366] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
498 Xu W, Chen Q, Wang Q, Sun Y, Wang S, Li A, Xu S, Røe OD, Wang M, Zhang R. JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells. Cell Death Dis. 2014;5:e1551. [PMID: 25476899 DOI: 10.1038/cddis.2014.517] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
499 He MM, Zhang DS, Wang F, Wang ZQ, Luo HY, Ren C, Jin Y, Chen DL, Xu RH. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma. World J Gastroenterol 2014; 20(1): 264-273 [PMID: 24415881 DOI: 10.3748/wjg.v20.i1.264] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
500 Tian X, Zhu X, Yan T, Yu C, Shen C, Hong J, Chen H, Fang JY. Differentially Expressed lncRNAs in Gastric Cancer Patients: A Potential Biomarker for Gastric Cancer Prognosis. J Cancer 2017;8:2575-86. [PMID: 28900495 DOI: 10.7150/jca.19980] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
501 Atsumi Y, Rino Y, Aoyama T, Okuda N, Kawahara S, Kazama K, Numata M, Tamagawa H, Oshima T, Yukawa N, Masuda M. A Gender Comparison of Bone Metabolic Changes After Gastric Cancer Surgery: A Prospective Observational Study. In Vivo 2021;35:2341-8. [PMID: 34182516 DOI: 10.21873/invivo.12510] [Reference Citation Analysis]
502 Ryu KW, Bae JM, Kim EM, An JY, Choi MG, Lee JH, Sohn TS. Long-term effect of simplified dietary education on the nutritional status of patients after a gastrectomy. PLoS One 2021;16:e0252168. [PMID: 34019591 DOI: 10.1371/journal.pone.0252168] [Reference Citation Analysis]
503 Skierucha M, Milne AN, Offerhaus GJA, Polkowski WP, Maciejewski R, Sitarz R. Molecular alterations in gastric cancer with special reference to the early-onset subtype. World J Gastroenterol 2016; 22(8): 2460-2474 [PMID: 26937134 DOI: 10.3748/wjg.v22.i8.2460] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
504 Eom BW, Ryu KW, Nam BH, Park Y, Lee HJ, Kim MC, Cho GS, Kim CY, Ryu SW, Shin DW, Hyung WJ, Lee JH. Survival nomogram for curatively resected Korean gastric cancer patients: multicenter retrospective analysis with external validation. PLoS One 2015;10:e0119671. [PMID: 25723182 DOI: 10.1371/journal.pone.0119671] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
505 Maezawa Y, Sakamaki K, Oue N, Kimura Y, Hashimoto I, Hara K, Kano K, Aoyama T, Hiroshima Y, Yamada T, Yamamoto N, Ogata T, Ito H, Cho H, Shiozawa M, Yoshikawa T, Morinaga S, Rino Y, Yasui W, Masuda M, Miyagi Y, Oshima T. High gamma-glutamyl hydrolase and low folylpolyglutamate synthetase expression as prognostic biomarkers in patients with locally advanced gastric cancer who were administrated postoperative adjuvant chemotherapy with S-1. J Cancer Res Clin Oncol 2020;146:75-86. [PMID: 31754833 DOI: 10.1007/s00432-019-03087-8] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
506 Douridas GN, Fountoulakis A, Souglakos J, Gourtsoyianni S, Vini L, Levidou G, Liakakos T, Agalianos C, Dervenis C, Kalogeridi MA, Karavokyros I, Koumarianou A, Kountourakis P, Oikonomopoulos G, Economopoulou P, Sgouros J, Sgouros SN, Stamou K, Triantopoulou C, Zacharoulis D, Gouvas N, Xynos E. Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer. Updates Surg 2020;72:1-19. [PMID: 32112342 DOI: 10.1007/s13304-020-00723-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
507 Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Son T, Jung MR, Heo MH, Kim HK, Park C, Yoo CH, Choi JH, Zang DY, Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Cho SH, Ryu SW, Kook MC, Ryoo BY, Kim HK, Yoo MW, Lee NS, Lee SH, Kim G, Lee Y, Lee JH, Noh SH. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol 2021;39:2903-13. [PMID: 34133211 DOI: 10.1200/JCO.20.02914] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
508 Barreto SG, Windsor JA. Redefining early gastric cancer. Surg Endosc. 2015;Epub ahead of print. [PMID: 25829068 DOI: 10.1007/s00464-015-4184-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
509 Meng QB, Kang WM, Yu JC, Liu YQ, Ma ZQ, Zhou L, Cui QC, Zhou WX. Overexpression of eukaryotic translation initiation factor 5A2 (EIF5A2) correlates with cell aggressiveness and poor survival in gastric cancer. PLoS One. 2015;10:e0119229. [PMID: 25793713 DOI: 10.1371/journal.pone.0119229] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 5.2] [Reference Citation Analysis]
510 Choi YY, Noh SH, Cheong JH. Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives. J Pathol Transl Med. 2016;50:1-9. [PMID: 26498010 DOI: 10.4132/jptm.2015.09.10] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
511 Park SC, Chun HJ. Chemotherapy for advanced gastric cancer: review and update of current practices. Gut Liver. 2013;7:385-393. [PMID: 23898376 DOI: 10.5009/gnl.2013.7.4.385] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
512 Mulazzani GEG, Corti F, Della Valle S, Di Bartolomeo M. Nutritional Support Indications in Gastroesophageal Cancer Patients: From Perioperative to Palliative Systemic Therapy. A Comprehensive Review of the Last Decade. Nutrients 2021;13:2766. [PMID: 34444926 DOI: 10.3390/nu13082766] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
513 Zhang K, Lu C, Huang X, Cui J, Li J, Gao Y, Liang W, Liu Y, Sun Y, Liu H, Wei B, Chen L. Long noncoding RNA AOC4P regulates tumor cell proliferation and invasion by epithelial-mesenchymal transition in gastric cancer. Therap Adv Gastroenterol 2019;12:1756284819827697. [PMID: 30815034 DOI: 10.1177/1756284819827697] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
514 Takahashi T, Saikawa Y, Kitagawa Y. Gastric cancer: current status of diagnosis and treatment. Cancers (Basel). 2013;5:48-63. [PMID: 24216698 DOI: 10.3390/cancers5010048] [Cited by in Crossref: 102] [Cited by in F6Publishing: 103] [Article Influence: 12.8] [Reference Citation Analysis]
515 Satake H, Miki A, Kondo M, Kotake T, Okita Y, Hatachi Y, Yasui H, Imai Y, Ichikawa C, Murotani K, Hashida H, Kobayashi H, Kotaka M, Kato T, Kaihara S, Tsuji A. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI). ESMO Open 2017;2:e000130. [PMID: 28761726 DOI: 10.1136/esmoopen-2016-000130] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
516 Sun JM. Adjuvant Therapy for Esophageal Squamous Cell Carcinoma. Korean J Thorac Cardiovasc Surg 2020;53:168-71. [PMID: 32793447 DOI: 10.5090/kjtcs.2020.53.4.168] [Reference Citation Analysis]
517 Kim SM. Cellular and Molecular Mechanisms of 3,3'-Diindolylmethane in Gastrointestinal Cancer. Int J Mol Sci 2016;17:E1155. [PMID: 27447608 DOI: 10.3390/ijms17071155] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
518 Huang ZN, Desiderio J, Chen QY, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Lu J, Cao LL, Lin M, Tu RH, Lin JL, Zheng HL, Huang CM. Indications for adjuvant chemotherapy in patients with AJCC stage IIa T3N0M0 and T1N2M0 gastric cancer-an east and west multicenter study. BMC Gastroenterol 2019;19:205. [PMID: 31791240 DOI: 10.1186/s12876-019-1096-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
519 Yang Q, Wei Y, Chen YX, Zhou SW, Jiang ZM, Xie DR. Indirect comparison showed survival benefit from adjuvant chemoradiotherapy in completely resected gastric cancer with d2 lymphadenectomy. Gastroenterol Res Pract 2013;2013:634929. [PMID: 24194750 DOI: 10.1155/2013/634929] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
520 Aoyama T, Fujikawa H, Cho H, Ogata T, Shirai J, Hayashi T, Rino Y, Masuda M, Oba MS, Morita S. A methylene blue-assisted technique for harvesting lymph nodes after radical surgery for gastric cancer: a prospective, randomized, controlled study. Am J Surg Pathol. 2015;39:266-273. [PMID: 25356528 DOI: 10.1097/pas.0000000000000336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
521 Park JK, Seo JS, Lee SK, Chan KK, Kuh HJ. Combinatorial Antitumor Activity of Oxaliplatin with Epigenetic Modifying Agents, 5-Aza-CdR and FK228, in Human Gastric Cancer Cells. Biomol Ther (Seoul) 2018;26:591-8. [PMID: 30173503 DOI: 10.4062/biomolther.2018.061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
522 Jang SH, Jung YJ, Kim MG, Kwon SJ. The Prognostic Significance of Compliance with Postoperative Adjuvant Chemotherapy in Patients with Stage III Gastric Cancer: an Observational Study. J Gastric Cancer. 2018;18:48-57. [PMID: 29629220 DOI: 10.5230/jgc.2018.18.e4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
523 Zhang Q, Qian Y, Yin Y. Comparison of S-1-based vs. capecitabine-based adjuvant chemotherapy for patients with gastric cancer: a systematic review and meta-analysis. Eur J Clin Pharmacol 2021. [PMID: 34275019 DOI: 10.1007/s00228-021-03187-w] [Reference Citation Analysis]
524 Kim HJ, Oh SC. Novel Systemic Therapies for Advanced Gastric Cancer. J Gastric Cancer 2018;18:1-19. [PMID: 29629216 DOI: 10.5230/jgc.2018.18.e3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
525 Chen L, Zhang C, Yao Z, Cui M, Xing J, Yang H, Zhang N, Liu M, Xu K, Tan F, Li Y, Jiang B, Su X. Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study. BMC Cancer 2021;21:974. [PMID: 34461860 DOI: 10.1186/s12885-021-08717-4] [Reference Citation Analysis]
526 Zhang P, Shi L, Zhang T, Hong L, He W, Cao P, Shen X, Zheng P, Xia Y, Zou P. Piperlongumine potentiates the antitumor efficacy of oxaliplatin through ROS induction in gastric cancer cells. Cell Oncol (Dordr) 2019;42:847-60. [PMID: 31493144 DOI: 10.1007/s13402-019-00471-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
527 Han R, Wei J, Zhang H, Su X, Chu X, Chen Y, Gong Y, Wang X, Shi J, Chen J. Influence of TS (rs34743033) and RUNX1 (rs2014300) gene polymorphisms on survival outcomes of fluorouracil-based chemotherapy in Chinese advanced gastric cancer patients. Cancer Manag Res 2018;10:1429-37. [PMID: 29922087 DOI: 10.2147/CMAR.S158647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
528 Yan H, Chen Y, Yang Z, Li Z, Che X, Xiao J, Liu Y, Qu X. An Immune Cell Signature Is Associated With Disease-Free Survival and Adjuvant Chemosensitivity of Patients With Resectable Gastric Cancer. Front Immunol 2020;11:621623. [PMID: 33613554 DOI: 10.3389/fimmu.2020.621623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]